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Type 1 and F17-like Pili Promote the Establishment of the Uropathogenic E. coli Intestinal 
Reservoir. 
By 
Caitlin N. Spaulding 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2017 
Dr. Scott J. Hultgren, Chair 
 
 Urinary tract infections (UTI) affect over 150 million individuals worldwide every year. 
These infections are associated with significant morbidity and have a sizeable economic impact, 
with $5 billion being spent on UTI treatment in the USA annually. Uropathogenic E. coli 
(UPEC) are responsible for 80% of community acquired UTIs and 65% of nosocomial UTI. The 
current standard of care for UTI is antibiotic therapy. However, 30-50% of women experience 
recurrent UTI (rUTI) despite receiving antibiotic therapy. The prevalence of single and multi-
drug resistant UPEC strains has led to increased reliance on carbepenems, which are primarily 
reserved for multi-drug resistant infections, to treat an increasing number of patients. 
Consequently E. coli strains resistant to colistin, a drug of last resort for treating carbapenem-
xi 
 
resistant Enterobacteriaceae, have now been isolated in over 30 counties. The rate at which drug-
resistant E. coli are spreading across the globe emphasizes the urgent nature of the antibiotic-
resistance crisis we currently face and the dire need for new, antibiotic-sparing therapies that 
target UPEC virulence factors. To colonize host tissue, E. coli encode chaperone usher pathway 
(CUP) pili and single UPEC strains can encode up to 16 distinct CUP pilus operons. Although 
CUP pilus types that promote UPEC colonization of the urinary tract have been identified, no 
studies investigating a role for CUP pilus types in UPEC intestinal colonization have been 
published. Still, leading models of infection posit that UPEC in the gut seed UTI by being shed 
in the feces, and then colonizing the peri-urethral or vaginal tissue and subsequently ascending 
through the urethra to access the bladder. Using a mouse model of UPEC intestinal colonization I 
found that two (CUP) pili, F17-like pili and type 1 pili, provide a fitness advantages for UPEC in 
the gut. The X-ray crystal structure of the F17-like pilus adhesin lectin domain, coupled with 
molecular studies of glycan binding, disclosed a ligand specificity distinct from other pilus types 
known to facilitate gastrointestinal colonization. While phylogenomic studies revealed that F17-
like pili are closely related to pilus types carried by intestinal pathogens, but are restricted to 
extra-intestinal pathogenic E. coli. Moreover, I found that high-affinity mannose analogues 
(mannosides) that target the function of type 1 pili and effectively treat UTI reduce intestinal 
colonization by clinical UPEC isolates, including a multi-drug resistant strain, without disrupting 
gut microbiota structure. By decreasing the intestinal UPEC reservoir that seeds bladder 
infection, mannosides could significantly reduce the rate of UTI and rUTI. Further, mannosides 
act like a molecular scalpel, specifically targeting intestinal UPEC with minimal effects on the 
overall gut microbiota. Ultimately, therapies like mannosides, which selectively target 
colonization by a specific pathogen, have potential to revolutionize treatment and prevention of 
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rUTI. Take together, this dissertation provides invaluable tools and insights into the understudied 
UPEC intestinal reservoir 
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Chapter 1: Adhesive Pili in UTI Pathogenesis 
and Drug Development 
From: 
 Adhesive Pili in UTI Pathogenesis and Drug Development 
Caitlin N. Spaulding and Scott J. Hultgren 
 
Pathogens 2016, 5(1), 30. doi: 10.3390/pathogens5010030. PMID: 26999218 
Copyright © 2016, Molecular Diversity Preservation International (MDPI). All Rights Reserved. 
 
Abstract 
 Urinary tract infections (UTIs) are one of the most common bacterial infections, affecting 
150 million people each year worldwide. High recurrence rates and increasing antimicrobial 
resistance among uropathogens are making it imperative to develop alternative strategies for the 
treatment and prevention of this common infection. In this Review, we discuss how understanding 
the: (i) molecular and biophysical basis of host-pathogen interactions; (ii) consequences of the 
molecular cross-talk at the host pathogen interface in terms of disease progression; and (iii) 
pathophysiology of UTIs is leading to efforts to translate this knowledge into novel therapeutics 
to treat and prevent these infections. 
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Introduction 
Urinary tract infections (UTIs) can be acquired in the community or hospital setting and are 
one of the most common bacterial infections that occur, affecting more than 150 million people 
worldwide each year [1–3]. UTI is clinically divided into two major infections, characterized by 
the localization of the bacteria in the urinary tract, cystitis and pyelonephritis. Cystitis, or lower 
UTI, is infection of the bladder. Once in the bladder, bacteria can ascend the ureters and colonize 
the kidneys, causing pyelonephritis or upper UTI. While the incidence of pyelonephritis is fairly 
low (~0.3%–0.6%) it is particularly dangerous as uncontrolled bacterial infection can spread to 
the bloodstream, causing sepsis (which occurs in ~2% of pyelonephritis cases) [4,5]. UTIs are 
also categorized as uncomplicated or complicated infections. Complicated UTI occurs in patients 
with: (i) functional or structural urinary tract abnormalities; (ii) renal failure; (iii) 
immunosuppression; (iv) pregnancy; and/or (v) foreign bodies, such as indwelling catheters, 
placed within their urinary tract [6–8]. Catheter-associated UTIs (CAUTI), make up 70%–80% 
of all complicated UTI and are the most common type of nosocomial infection [4,9]. CAUTI are 
of particular concern as they result in high morbidity, increased mortality and are the most 
common cause of secondary sepsis in hospital patients. While complicated UTI affects 
individuals of both genders, uncomplicated UTI primarily affects otherwise healthy women [10]. 
Pyelonephritis often occurs in healthy, non-pregnant women but can be categorized as a 
complicated UTI because of the potential of developing a blood stream infection. For women, 
the lifetime risk of developing an uncomplicated UTI approaches 60% [5]. Of these women who 
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experience an initial UTI, 20%–30% will go on to experience a recurrent infection (rUTI) within 
4–6 months, despite receiving appropriate antibiotic therapy [5,11]. To combat rUTI, these 
women are treated with frequent antibiotic therapy often to be taken at the time that symptoms 
arise or immediately following sexual intercourse [6]. However, a subset of these women will 
continue to experience rUTI as frequently as six or more times a year [12]. Due to its prevalence 
and high rates of recurrence, UTI is associated with significant economic costs. The financial 
burden of UTI in the United States, which reflects both direct medical costs and indirect costs 
such as lost work output and wages, is an estimated $5 billion annually [5]. These infections also 
result in significant patient morbidity resulting in serious deterioration in quality of life 
including: pain, discomfort, disruption of daily activities, and few treatment options other than 
long-term antibiotic prophylaxis [5,11,13]. 
While many bacterial organisms cause UTI, the most common causative agent of both 
uncomplicated and complicated UTI is the gram-negative pathogen uropathogenic Escherichia 
coli (E. coli) (UPEC). UPEC are responsible for 80%–90% of all uncomplicated UTI and 
approximately 65% of complicated UTIs [5,14,15]. Gram-positive Enterococcus species are the 
second leading cause of complicated UTI (11%) and the third leading cause of uncomplicated 
UTI (5%) [15]. The source population of UPEC and Enterococcus that lead to UTI is thought to 
be the gastrointestinal tract, where they can reside as either commensal or transient members of 
the gut microbiota [11,16,17]. When present in the gut, UPEC or Enterococcus spp. can be shed 
in the feces, inoculating peri-urethral or vaginal areas, and are subsequently introduced into the 
urinary tract during periods of physical manipulation such as during sexual activity or 
catheterization (Figure 1A) [18]. Upon entering the bladder, uropathogens must bind to an 
available epithelial receptor and/or, if present, abiotic-surface to establish and maintain 
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colonization. UPEC and enterococcal species both accomplish this through the expression of 
distinctive adhesive pili on their surface. After creating a foothold in the bladder, uropathogens 
employ a myriad of additional virulence factors to establish bladder colonization in the face of an 
active immune response, micturition, and rapid epithelial cell exfoliation. Historically, antibiotics 
have been used, very successfully, to treat patients with UTI. However, the rise of single and 
multi-drug resistant uropathogens as well as high rates of recurrence in women infected with 
both antibiotic sensitive and drug-resistant uropathogens has become a major concern, 
highlighting the need to develop alternative strategies to treat patients with UTI and CAUTI. In 
this review, we will discuss the role of adhesive pili during UTI or CAUTI. Here we will focus 
mainly on UTI and CAUTI caused by UPEC and Enterococcus spp. due to the high prevalence 
of these pathogens in community-acquired and nosocomial infections. We will also explore the 
development of alternative, non-antibiotic treatment strategies that target adhesive pili in order to 
prevent UPEC and Enterococcus spp. from initiating infection and thus causing disease. 
The Role of Chaperone-Usher Pathway (CUP) Pili in UPEC Mediated UTI 
CUP Pilus Assembly Mechanisms 
Upon entering the bladder, UPEC must first adhere to the bladder epithelium, also referred 
to as the urothelium, or risk clearance during urine voiding. Recognition and attachment to host 
and environmental surfaces is mediated through the expression of non-flagellar, adhesive, 
extracellular fibers, called pili that bind to receptors present on the host cell surface. In UPEC, 
many of these adhesive pili belong to a large, conserved family of pili called the chaperone-usher 
pathway (CUP) pili [20]. CUP pili are assembled by the corresponding chaperone-usher 
machinery, which are encoded by operons that contain all the dedicated genetic information 
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necessary to assemble a mature pilus: an outer-membrane pore-forming usher protein, a 
periplasmic chaperone protein, pilus subunits, and in most cases, a tip adhesin protein. The first 
crystal structure of a CUP chaperone, PapD, which is involved in the assembly of P pili, revealed 
that it consists of two-immunoglobulin (Ig) domains [21]. Two key amino acid residues, R8 and 
K112, present in the cleft of the chaperone were subsequently identified as the active site of the 
protein [22]. Unlike the chaperone, pilus subunits are composed of an incomplete Ig fold, which 
lacks the C-terminal beta strand and requires the assistance of the dedicated chaperone for 
folding and stability (Figure 2B,D). Chaperone-assisted folding occurs by a reaction termed 
donor strand complementation (DSC) in which conserved alternating exposed hydrophobic 
residues on the chaperone’s G1 strand are buried in complementary pockets in the pilus subunit, 
allowing for the completion of the subunits Ig fold (Figure 2C) [23,24]. This interaction allows 
pilus subunits to fold into a primed, high-energy state in complex with the chaperone, ultimately 
allowing the subunits to be targeted to the outer membrane usher (Figure 2E). The usher, a gated 
channel, is made up of five functional domains: a 24 stranded transmembrane β-barrel 
translocation domain (TD), a β-sandwich plug (PLUG) that resides in the pore of the TD in the 
apo-usher, an N-terminal periplasmic domain (NTD) and two C-terminal periplasmic domains 
(CTD1 and 2) [25–29]. The usher catalyzes pilus assembly by driving subunit polymerization in 
a concerted reaction termed donor strand exchange (DSE) (Figure 2E,F) [30–33]. Pilus subunits, 
excluding the adhesin, encode an N-terminal extension (Nte) comprised of conserved alternating 
hydrophobic residues. DSE occurs when the chaperone is displaced and an incoming subunit’s 
Nte zips into the previously chaperone-bound groove of a nascently incorporated subunit at the 
growing terminus of the pilus. This “zip-in-zip-out mechanism” allows for the final folding of 
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the pilus subunit, such that every subunit in the pilus completes the Ig fold of its neighbor 
(Figure 2F). 
The Role of Type 1 Pili during Uncomplicated UTI 
A hallmark of the luminal surface of urothelial cells, also called superficial facet cells, are 
the presence of uroplakin plaques, which consist of 4 uroplakin integral membrane proteins, that 
function as a barrier between the toxic contents of the bladder and the underlying urothelium 
[34,35]. The surface of the uroplakin is studded with mannose [36,37]. The tip adhesin for type 1 
pili, FimH, binds mannose with stereochemical specificity. Therefore, upon entering the bladder, 
FimH is able to bind mannosylated residues on the bladder surface, such as those found on 
uroplakin as well as β1-α3 integrin receptors (Figure 1B) [36,38–40]. FimH mediated interaction 
with the urothelium induces a signaling cascade that activates Rho family GTPases and results in 
actin rearrangement within urothelial cells, promoting UPEC invasion (Figure 1C,D) [38,41,42]. 
Studies in mice have revealed that once inside superficial facet cells, UPEC are able to escape 
the endocytic vesicle, via unknown mechanisms, into the cytoplasm where they replicate rapidly 
forming biofilm-like communities called intracellular bacterial communities (IBCs) (Figure 
1D,E) [43–45]. In mice, type 1 pili are not only required for cellular adherence and invasion but 
also for the aggregation of bacteria into an IBC in the host cell cytoplasm [46]. Mouse studies 
have shown that invasion is a critical step in UPEC pathogenesis in naïve mice, allowing the 
bacteria to rapidly replicate in a niche protected from many innate immune defense mechanisms 
and antibiotics. UPEC that cannot invade the urothelium, like those lacking FimH, are quickly 
cleared from the bladder, emphasizing the importance of this intracellular stage to the success of 
the pathogen [46]. Mature IBCs contain approximately 104 bacteria. Upon maturation, bacteria 
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within the IBC adopt a filamentous morphology and disperse from the biomass, fluxing out of 
the cell and back into the bladder lumen where they can adhere to and/or invade adjacent facet 
cells or exposed transitional epithelial cells (Figure 1G,H) [43,44,47,48]. Importantly, evidence of 
IBCs and bacterial filaments have been observed in women suffering from acute UTI, one to two 
days post self-reported sexual intercourse, but not in healthy controls or infections caused by 
Gram-positive organisms, which do not form IBCs [49]. IBCs have also been observed in urine 
from children with an acute UTI and their presence was correlated with recurrent UTI, 
supporting the validity of their importance in pathogenesis and the ability of the mouse model to 
recapitulate human disease [50]. 
While the collection of tissue biopsies from women with UTI is generally contraindicated, 
one study of tissue biopsies demonstrated the presence of intracellular UPEC [51]. In urine from 
UTI patients and/or mice, the expression of type 1 pili has been reported to be variable [52–54]. 
Several studies, in mice and humans, have demonstrated that UPEC attached to shed epithelial 
cells in the urine express type 1 pili while planktonic UPEC found in the urine tend to be 
nonpiliated [54,55]. This suggests that the expression of type 1 pili is niche specific, with type 1 
pili being expressed by UPEC that are attached to the epithelial surface.  
In addition to type 1 pili, a mosaic of UPEC virulence factors including adhesins, toxins, 
capsule, siderophores, and flagella have been identified and characterized [39,56–61]; however 
the direct contribution of these putative urovirulence factors has not been exhaustively studied. 
In a recent comprehensive genomic analysis of 43 UPEC isolates, we found that “core” genes, 
defined as genes shared between all E. coli, constituted approximately 60% of each strain’s 
genome. Further, we were unable to find any single set of genes that accurately delineated UPEC 
from non-UPEC strains (Schreiber and Hultgren, personal communication). The lack of a strict 
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‘genetic’ definition of UPEC indicates that, in most cases, urovirulence in UPEC is more 
complicated than carriage of a set of virulence-associated genes that are missing in non-UPEC 
strains. Instead urovirulence in UPEC strains may be defined by alternative characteristics, like 
propensity to certain patterns of gene expression, as is seen with niche specific expression of 
type 1 pili in the bladder [54, 55], or the carriage of different alleles of core genes. There are a 
number of different alleles of FimH, described later in this review, that alter the affinity of the 
adhesin for its ligand and may be associated with more virulent strains. These alternative 
characteristics may explain how genes that are highly conserved in both UPEC and non-UPEC 
strains, like those that encode type 1 pili, contribute to pathogenesis during UTI. 
The Host Response to Type 1 Piliated UPEC 
The host has evolved several mechanisms to respond to type 1 pilus mediated binding in a 
manner that favors bacterial clearance or killing. Caspase-dependent apoptosis and exfoliation of 
superficial facet cells is observed within hours of type 1 pili binding and invasion in C57BL/6 
mice [39,62,63]. This promotes the clearance of infected cells from the host during micturition 
(Figure 1F). In the absence of cell exfoliation, the host can expel UPEC directly from an invaded 
cell via a TLR-4 dependent mechanism, reducing the number of successful UPEC invasion 
events and decreasing the overall number of IBCs formed during acute infection (Figure 1C) 
[19]. UPEC interactions with the host also leads to the robust recruitment of immune cells, 
mainly neutrophils and inflammatory monocytes, to the urinary tract as well as the up regulation 
of pro-inflammatory cytokines which drive the mobilization of additional immune effectors [64–
68]. Several natural allele variants of FimH exist. The residues in the mannose-binding pocket of 
FimH are invariant in all sequenced UPEC isolates [37,69], however there is diversity outside of 
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this pocket, including at a cluster of amino acids that are positively-selected in UPEC strains 
[69]. Interestingly, mutations in these positively selected residues results in distinct FimH alleles 
that are skewed into either elongated or compact conformations, which have been observed in 
several X-ray crystal structures of FimH [25,26,70]. The elongated conformation corresponds to 
the mannose binding conformation whereas the compact form binds mannose only weakly or not 
at all [69,71,72]. When FimH is bound to the FimC chaperone, it adopts an elongated 
conformation [26] however, upon its incorporation into the tip of the pilus, it can convert to a 
compact conformation with an altered mannose-binding pocket [25,70]. In the FimCH complex, 
all of the FimH allele variants tested have a high affinity for mannose. However, when 
incorporated into a tip-like state, following a DSE reaction with the FimG adaptor, FimH 
variants differ greatly in their mannose affinity suggesting that depending on the allele, FimH is 
skewed toward either an elongated or compact form after its incorporation into the tip [73]. 
Interestingly, UPEC strains containing distinct FimH alleles also display altered levels of 
pathogenicity during acute and chronic UTI in C57BL/6 [74] and C3H/HeN mice [73]. Of 
particular interest we found that specific mutations in two positively selected residues, A27 and 
V163, result in a FimH variant (FimH(A27V/V163A)) that resides within a tip-like complex 
predominantly in a high-affinity mannose binding conformation [73]. Surprisingly, this FimH 
allele is severely attenuated in a cystitis model [69,73]. These findings support the hypothesis 
that FimH resides in an equilibrium of mannose-binding and non-binding conformations, which 
are governed, in part, by the identity of select residues that are under positive selection in UPEC 
isolates. The inter-conversion between high and low mannose-binding conformations is likely 
important for tissue-binding and/or immune evasion, which may begin to explain why the 
FimH(A27V/V163A) variant, which appears to be “locked” in a high-affinity elongated state is 
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unable to cause infection in vivo despite its high-affinity for mannose. These findings may be 
related to the important observation made by others that FimH conformation is influenced by 
shear force leading to a “catch bond” model of FimH function [70–72,75,76]. Thus, the ability of 
FimH to be incorporated into a pilus tip to interconvert into different conformations affects 
virulence. 
The Biophysics of FimH Structure and Function 
Several natural allele variants of FimH exist. The residues in the mannose-binding pocket of 
FimH are invariant in all sequenced UPEC isolates [37,69], however there is diversity outside of 
this pocket, including at a cluster of amino acids that are positively-selected in UPEC strains 
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that are skewed into either elongated or compact conformations, which have been observed in 
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at all [69,71,72]. When FimH is bound to the FimC chaperone, it adopts an elongated 
conformation [26] however, upon its incorporation into the tip of the pilus, it can convert to a 
compact conformation with an altered mannose-binding pocket [25,70]. In the FimCH complex, 
all of the FimH allele variants tested have a high affinity for mannose. However, when 
incorporated into a tip-like state, following a DSE reaction with the FimG adaptor, FimH 
variants differ greatly in their mannose affinity suggesting that depending on the allele, FimH is 
skewed toward either an elongated or compact form after its incorporation into the tip [73]. 
Interestingly, UPEC strains containing distinct FimH alleles also display altered levels of 
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particular interest we found that specific mutations in two positively selected residues, A27 and 
V163, result in a FimH variant (FimH(A27V/V163A)) that resides within a tip-like complex 
predominantly in a high-affinity mannose binding conformation [73]. Surprisingly, this FimH 
allele is severely attenuated in a cystitis model [69,73]. These findings support the hypothesis 
that FimH resides in an equilibrium of mannose-binding and non-binding conformations, which 
are governed, in part, by the identity of select residues that are under positive selection in UPEC 
isolates. The inter-conversion between high and low mannose-binding conformations is likely 
important for tissue-binding and/or immune evasion, which may begin to explain why the 
FimH(A27V/V163A) variant, which appears to be “locked” in a high-affinity elongated state is 
unable to cause infection in vivo despite its high-affinity for mannose. These findings may be 
related to the important observation made by others that FimH conformation is influenced by 
shear force leading to a “catch bond” model of FimH function [70–72,75,76]. Thus, the ability of 
FimH to be incorporated into a pilus tip to interconvert into different conformations affects 
virulence. 
The Role of P Pili in Pyelonephritis 
The ability of UPEC to ascend from the bladder to the upper urinary tract likely involves 
many genetic and environmental factors, one of which is thought to be the up-regulation of P pili 
and corresponding down-regulation of type 1 pili [77]. P pili, which are encoded by the pap 
operon, mediate adhesion of UPEC to kidney tissue resulting in pyelonephritis [61,78–80]. This 
binding is dependent on the expression of the P pilus tip adhesin, PapG [56,81]. Three alleles of 
PapG exist (PapG-I, -II, and -III) and each allele shows a distinct affinity for a series of Galα1-
4Gal containing glycolipid receptors, which are expressed to various degrees in the kidneys and 
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ureters of mammals [82]. Human kidneys, for example, abundantly express the ligands for PapG-
II, globoside, and thus are colonized with UPEC that express PapG-II alleles. Conversely, PapG-
III binds strongly to Forssman glycolipid, which is present in dog but not in human kidneys. 
Thus, different alleles of PapG mediate host tropisms [83–85]. 
Identifying Roles for Additional CUP Pilus Types during Disease 
A recent analysis of 35 Escherichia spp. genomes and 132 plasmids identified a total of 458 
CUP pili operons, representing 38 distinct CUP pilus types based on usher phylogeny [86,87]. 
CUP pili tipped with specific adhesins provides E. coli the ability to bind to distinct ligands with 
stereo-chemical specificity. Single UPEC strains were found to carry as many as 16 distinct, 
intact CUP pilus systems that likely aid UPEC strains in their colonization of many host niches, 
including the gut, vagina, urethra, bladder, and kidneys. Thus, it is likely that the retention of 
many distinct CUP pilus types reflects the adaptation to broad environmental and host niches and 
their function in facilitating the various tropisms of E. coli [88]. Aside from type 1 and P pili, 
UPEC strains encode a number of additional CUP pilus types for which a role in UPEC 
pathogenesis is minimally defined or completely undetermined. S pili are known to bind 
sialosyloligosaccaride residues in host cells and likely mediate infection of the ureters and 
kidneys [89]. Clinical isolates containing S pili are often associated with more severe outcomes 
in patients with UTI, including: pyelonephritis, sepsis, and meningitis. The Dr pili adhesin has 
been shown to bind type IV collagen and decay-accelerating factor (DAF), both of which are 
expressed in human kidneys. Dr pili enable UPEC colonization of the mouse renal interstitial 
basement membrane [90,91]. The roles for CUP pili, including F1C, F9, Ygi, Yad, and Auf, have 
been briefly explored and have been recently reviewed [92–94]. Identifying roles for additional 
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CUP pilus types will enhance our overall knowledge of UTI pathogenesis and may provide novel 
drug targets to treat patients with UTI. 
Outcomes of UTI: Connecting Findings in Humans and Mice 
 Much of our understanding of UTI and rUTI pathogenesis comes from studies in mice. The 
development of murine models of acute and recurrent cystitis have allowed for many important 
advances in our understanding of UTI pathogenesis. However, it is also worth noting that the 
UTI mouse models, like all animal models, have limitations. Behavior, genetic, and environment 
differences between mice and humans make it challenging to translate all murine findings to 
humans [99]. Here we discuss advances in our understanding of UTI pathogenesis based on 
experiments performed in relevant mouse models and highlight how these findings have been 
recapitulated in clinical studies performed in women with UTI or rUTI. 
For women with UTI, several disease outcomes are possible, including: asymptomatic 
bacteruria (ABU), acute self-limiting infection, or chronic/recurrent UTI [5]. Placebo studies in 
women have shown that approximately 50% of UTIs do not resolve in the absence of effective 
antibiotic treatment, implying that cystitis is not always self-limiting. These findings highlight 
the importance of clinical intervention to resolve UTI and the developing crisis of emerging 
multi-drug resistant uropathogens [95,96]. In naïve mice, there are two major outcomes of UTI: 
(i) self-limiting acute infection that resolves within days of the initiation of infection with or 
without the formation of quiescent intracellular reservoirs (QIR); or (ii) persistent, high-titer 
bacteruria concomitant with high bladder bacterial burden and severe bladder inflammation 
which, in the absence of antibiotic intervention, can last for the lifetime of the animal and is 
referred to as chronic cystitis [100] (Figure 1H). The resolution of infection in mice is often 
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accompanied by QIR formation [97] (Figure 1I). The exfoliation response results in the exposure 
of the underlying transitional cells, which allows the subsequent invasion of UPEC into these 
cells. However, unlike superficial facet cells, the underlying transitional cells do not support IBC 
formation; instead UPEC establish QIRs, which are comprised of 8–12 dormant bacteria in 
Lamp1+ vesicles [97]. The mechanism of QIR formation is unknown, however, these reservoirs 
are able to reactivate and release UPEC back into the bladder lumen to initiate a new infection 
cycle [97,98]. Interestingly, the fate of disease in mice is determined by whether an acute host-
pathogen checkpoint, which is influenced by the genetic background of the mice, is triggered. 
C57BL/6 mice are resistant to chronic cystitis after a single infection; however, they can develop 
persistent bacteriuria and chronic cystitis when “superinfected”, by multiple transurethral 
inoculations within a 24 hour period [74]. Elevated levels of interleukin-6 (IL-6), keratinocyte 
cytokine (KC/CXCL1), and granulocyte colony-stimulating factor (G-CSF) in the serum of 
C57BL/6 mice prior to the second infection predicted the development of chronic cystitis [74]. 
These same cytokines have been found to precede chronic cystitis in singly infected C3H/HeN 
mice, which are prone to the development of chronic cystitis [100]. Superinfection of C3H/HeN 
mice within a six-hour period doubles the proportion of mice that developed chronic cystitis. 
Intracellular bacterial replication, regulated hemolysin (HlyA) expression, and caspase 1/11 
activation were essential for this increase [74]. The chronic bladder inflammation that 
accompanies chronic cystitis includes lymphonodular hyperplasia in the bladder submucosa and 
urothelial hyperplasia that results in the loss of superficial facet cells. Similar histological 
findings have been observed in humans suffering from persistent bacteriuria and rUTI [101,102]. 
Proteomic analysis of chronically infected bladders indicates that chronic inflammation also 
results in bladder epithelial remodeling, which may help to explain why mice that experience 
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chronic cystitis are more susceptible to rUTI upon further bacterial challenge weeks after 
antibiotic intervention and resolution of the initial infection [67]. Studies of mice with rUTI may 
also begin to explain why a history of UTI is a major risk factor for rUTI in women, highlighting 
the clinical relevance of this mouse model. Elevated soluble serum biomarkers that were 
predictive of rUTI were also detected in young women with UTI [67]. Interestingly, temperance 
of the neutrophil response during the first 24 hours of infection, by inhibition of cyclooxygenase-
2 (COX 2), protected mice from chronic and recurrent cystitis [67]. These findings may help to 
explain the outcome of a small clinical trial that compared the outcomes of women with UPEC 
UTI after being given a three-day course of either ciprofloxacin or ibuprofen. The study found no 
difference in UTI outcome between these two groups at four or seven days post treatment [103]. 
Another study found that symptomatically treating women suffering from uncomplicated UTI 
with ibuprofen (without any antibiotics) resolved infection in two-thirds of the study group 
[104]. These results indicate that ibuprofen, which works by inhibiting COX 1 and 2, may act to 
decrease the severity of UTI in these patients. However, the second study also found that women 
in the ibuprofen treated group suffered from more UTI symptoms (abdominal pain, increased 
frequency of urination, dysuria) and were more likely to develop pyelonephritis [104].  
The development of rUTI is likely a balance between bacterial factors and host genetics. 
Murine studies have indicated that the innate immune response is critical for combating UTI, 
which had been recapitulated in human clinical studies [105]. Therefore, mutations in the genes 
involved in this early immune response can greatly influence the susceptibility of a host to UTI. 
For example, certain polymorphisms and altered expression levels of innate immune genes, like 
Toll-like receptor 4 (TLR4) and CXCR1, have been associated with less severe symptomatic 
UTI but an increase in the development of ABU in women [105]. Alterations in the sequence or 
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expression of other innate immune genes, like IRF3 and CXCR1, have been associated with 
increased incidences of acute pyelonephritis [105]. 
Pili are Critical for the Establishment of UPEC and Enterococcus Mediated CAUTI 
The introduction of a catheter into the urinary tract provides an additional surface on which 
bacteria can adhere and establish infection. Uropathogens that are commonly associated with 
CAUTI, like those belonging to the Enterococcus genus, also encode a number of distinct 
adhesive factors and pili that permit attachment within the host. Of these factors, the 
endocarditis- and biofilm-associated (Ebp) pilus has recently been identified to play an essential 
role in the establishment and persistence of UTI in a catheterized mouse model [106–110]. Upon 
catheterization, implanted catheters are coated with host-derived fibrinogen and are subsequently 
bound by Ebp expressing Enterococcus faecalis (E. faecalis), a common enterococcal 
uropathogen [109]. The Ebp pilus binds fibrinogen via its tip adhesin, EbpA, which contains an 
N-terminal fibrinogen-binding domain [109]. The mechanism(s) by which fibrinogen enters the 
bladder is still under investigation but is likely due to bladder damage that occurs during the 
catheterization process and subsequent infection. Mechanical stress induced by insertion of the 
catheter into the bladder results in the induction of a robust inflammatory response and severe 
bladder edema in humans and mice [107,111–113]. Bladder inflammation, including increases in 
serum cytokines IL-1α and IL-6, and edema, is elevated further upon introduction of E. faecalis 
into the catheterized mouse [107]. Increases in IL-1α and IL-6 have been previously shown to 
stimulate the release of fibrinogen from the liver into the bloodstream as a part of the pro-
inflammatory response and circulating fibrinogen may then leak into the urinary tract via tissue 
damaged during catheterization. Once in the bladder, fibrinogen is deposited on the catheter, 
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providing a binding site for EbpA expressing E. faecalis. Catheterization and the subsequent 
inflammatory response are essential in mediating CAUTI, as mice infected with E. faecalis in the 
absence of a catheter are quickly cleared from the bladder [107]. Fibrinogen deposited onto the 
catheter surface not only enhances E. faecalis biofilm formation but also promotes growth, 
increasing the severity of the infection [109]. The ability to bind and utilize fibrinogen may be a 
general feature of infection in gram-positive bacteria, (as has been shown for Staphylococcus 
aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), and Group A streptococci) and 
potentially in some fungal pathogens (as was recently shown for Candida albicans) [114,115]. 
The Ebp pilus also plays a role in the transition of E. faecalis infection from the bladder to the 
kidneys. In E. faecalis, loss of the pilus reduces bacterial colonization of the kidneys and thus 
lowers the incidence of pyelonephritis in infected mice [110]. 
UPEC, the leading cause of complicated UTI, can also use CUP pili to colonize the bladder 
during catheterization [15,116]. However, unlike Enterococcal spp., UPEC does not rely on the 
presence of the catheter to propagate high levels of bacterial colonization. In a CAUTI mouse 
model, UPEC undergoes the same acute pathogenic lifecycle that is observed in cystitis models, 
including: invasion into the tissue, IBC formation and maturation, the formation of filaments, 
and the emergence of filamentous bacteria back into the bladder lumen [116]. However, in the 
presence of the catheter, UPEC does appear to have a more robust extracellular population 
during acute infection, which is likely due to UPEC colonization and subsequent biofilm 
formation on the surface of the catheter [116]. Interestingly, type 1 pili are required for biofilm 
formation and UPEC colonization of the catheter [116]. These studies continue to define the 
importance of type 1 pili as a virulence factor during uncomplicated and complicated UTI in 
mice. 
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Development of Pili-Based Alternative Treatments to Treat or Prevent UTI and CAUTI 
Pili are potential drug targets due to the critical roles they play in UTI and CAUTI 
pathogenesis. Our understanding of the molecular mechanisms by which pili function and impact 
disease has permitted the development of novel therapeutics, such as vaccines and small 
molecule inhibitors, that target pili and block infection by preventing colonization. While a role 
for pili during intestinal colonization by uropathogens is currently unstudied, identifying and 
targeting pili that do permit intestinal colonization would provide a unique opportunity to target 
the source of uropathogens that lead to downstream infections. 
Vaccines 
A number of promising vaccines that target a wide-range of UPEC virulence factors are 
currently in development [117–121]. The FimCH vaccine, a subunit vaccine targeting the type 1 
pilus adhesin FimH, is one such example. Significant protection was observed in subcutaneously 
vaccinated mice and cynomolgus monkeys given an intra-muscular vaccination, with the 
protected animals developing antigen-specific, long-lasting serum IgG antibodies [120,121]. 
Based on this data, it is presumed that the vaccine works by stimulating these FimH-specific IgG 
antibodies that block UPEC colonization of the bladder. Consistent with this, the polyclonal 
antibodies derived from vaccinated mice block FimH function and likely activate immune 
effector cells, like phagocytes and complement, for clearance of the infection [120,121]. The 
success of this vaccine in animal models highlights its potential as an alternative treatment to 
UTI in humans. A FimCH vaccine adjuvanted with PHAD (Avanti Polar Lipids, Alabaster, AL) 
is currently completing a Phase 1 human study. This study has enrolled about 67 women with 
and without a history of rUTI (personal communication, Gary Eldridge). 
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Other CUP pilus types are the focus of additional vaccine candidates. One such candidate is 
the PapDG subunit vaccine. P pili are strongly associated with pyelonephritis and as such have 
been designed to target UPEC and prevent complicated upper UTIs [61]. Intraperitoneal 
administration of the PapDG vaccine protects animals from infection and elicits a specific IgG 
antibody response in cynomolgus monkeys [118,122]. The Dr fimbriae represents another 
current vaccine target. Mice vaccinated with purified Dr fimbriae produce high titers of serum 
antibodies against the fimbriae but do not have lower colonization rates in either the bladder or 
kidneys [123].  
Recent findings revealed an essential role for the Ebp pilus and its adhesin, EbpA, during E. 
faecalis mediated CAUTI in mice. Interestingly, vaccinating mice with EbpA results in 
significant protection against subsequent E. faecalis CAUTI compared to unvaccinated mice or 
mice vaccinated with other Ebp pilus protein subunits [109). Vaccinating mice with only the N-
terminal portion of EbpA, which contains the fibrinogen-binding domain, is also sufficient to 
protect mice from subsequent infection and may provide a higher level of protection than 
vaccination with the entire adhesin. 
Small Molecular Inhibitors 
The importance of the FimH-mannose interaction during infection in mice has prompted 
studies that test the effects of oral treatment with D-mannose or mannose-analogs on UTI 
outcome. Oral D-mannose treatment has been shown in studies to work as well as antibiotics to 
prevent rUTI. One group found that women who received prophylaxis with D-mannose after an 
initial UTI had similar rates of rUTI as a group that received antibiotic prophylaxis, indicating 
that D-mannose may be useful to prevent rUTI [124]. Another strategy to prevent UPEC 
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pathogenesis has been the design of orally active, synthetic, small-molecule inhibitors of CUP 
pilus assembly or function. One such class of small molecule inhibitors are mannosides. 
Mannosides are mannose analogs that were rationally designed to bind within the mannose-
binding pocket of FimH with a high affinity and thus block pilus binding of FimH to host 
receptors (Figure 2) [125,126]. Studies in mouse models have demonstrated that mannosides are 
potent, fast acting and highly efficacious in the treatment of UTI and CAUTI [116,127–129], 
highlighting their potential as a novel therapeutic strategy for UTI. Mannoside treatment is 
especially promising as a novel antibiotic sparing therapeutic because they are effective against 
multi-drug resistant uropathogens [128]. While D-mannose and mannosides both appear to 
effectively block FimH-mannose interactions, mannosides have approximately a 1,000,000-fold 
increase in potency for inhibiting FimH, making them promising antibiotic-sparing therapeutics 
[125,130].  
Another class of compounds are pilicides, which are small, rationally designed 2-
pyridinones that block pilus assembly (Figure 2) [131,132]. Pilicides block assembly by binding 
to the pilus chaperone, preventing chaperone-pilus subunit-usher interactions that are 
fundamental for pilus biogenesis [133]. While pilicides were originally designed to target type 1 
pilus assembly, recent studies have found that pilicide treatment disrupts assembly of at least 
four-CUP pilus types (type 1-, P-, S-, and Dr- pili) as well as flagellar motility [134,135]. The 
ability of pilicides to target multiple pilus types makes it an extremely valuable treatment option. 
Conclusions 
Complicated and uncomplicated UTI are extremely common, affecting a large portion of the 
global population. The high rate of infection and recurrence of UTIs, their monetary cost, their 
physical burden, and the increasing occurrence of antibiotic resistant uropathogens emphasize 
21 
 
the need for effective treatments to combat the common causative agents of UTI and CAUTI, 
like UPEC and Enterococcus strains. Understanding the molecular mechanisms by which 
uropathogens are able to cause disease is the first step to identifying novel drug targets. Adhesive 
pili, like type 1, P, and Ebp, have been shown to play essential roles in UTI pathogenesis in 
mouse models and provide potential drug targets that may greatly reduce or prevent infection in 
patients. While the mouse models of uncomplicated UTI and CAUTI have been shown to mimic 
disease in human patients, the success of vaccine and small molecular inhibitor therapies against 
these pili in humans is dependent on determining the efficacy of these treatments in clinical 
trials. 
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Figures 
Figure 1. Uropathogenic E. coli (UPEC) pathogenic cascade during cystitis. (A) UPEC 
residing in the gut are shed in the feces and colonize the peri-urethral and vaginal areas 
before ascending into the bladder. Upon accessing the bladder, UPEC adhere to the surface 
of superficial facet cells that line the bladder lumen in a type 1 pili dependent manner (B). 
Adherent bacteria invade into the facet cells and are either expelled back into the lumen by 
the cell in a TLR-4 dependent manner [19] (C) or escape from the endocytic vesicle into the 
cytoplasm (D). Upon invasion, bacteria replicate in the cytoplasm forming intracellular 
bacterial communities (IBCs) (E). One host mechanism of defense against intracellular 
UPEC is the shedding of urothelial cells into the urine (F), which reduces the overall 
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number of UPEC in the bladder. During the late stages of IBC formation, filamentous 
bacteria dissociate from the IBC, burst out of the cell and back into the bladder lumen where 
they remain or can invade an adjacent facet cell (G). There are two potential outcomes of 
infection: chronic cystitis or resolution of infection. Uncontrolled bacterial replication in the 
urine occurs in mice that develop chronic cystitis (H). In mice that resolve infection, small 
pockets of bacteria, termed quiescent intracellular reservoirs (QIRs), form and reside in the 
underlying urothelium and may seed future rUTI (I). 
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Figure 2. Mannosides and Pilicides prevent uropathogenic E. coli (UPEC) urinary tract 
infections (UTI) by targeting the function or formation of type 1 pili. (A,G) Unfolded 
pilus subunits are secreted to the periplasm by the Sec apparatus. (B,H) Upon entering the 
periplasm, unfolded subunits immediately interact with the cognate chaperone (FimC). 
Subunits have an incomplete Ig-like fold which must be completed in order to properly fold. 
In a process called donor strand complementation (DSC) FimC donates its G1 β-stand to the 
subunit, stabilizing it (C,I). Subunits that do not interact with FimC are unable to fold 
correctly and are degraded (D). The chaperone then delivers the subunit to the outer member 
usher, FimD (E). Upon reaching FimD the subunit is assembled into the maturing pilus via 
donor stand exchange (DSE) with the adjacent pilus subunit (F). Mannosides prevent type 1 
pilus function by binding, in an irreversible manner, to FimH and therefore prevent the 
interaction of FimH and mannose on the bladder surface (G). Pilicide works by halting pilus 
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assembly. These molecules enter the periplasm (J) and bind to the pilus chaperone, halting 
assembly (K). 
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Abstract 
 Uropathogenic E. coli (UPEC) are responsible for 80% of community-acquired and 65% 
of nosocomial urinary tract infections (UTI)1,2, which together affect 150 million people 
annually3. Despite effective antibiotic therapy, 30-50% of patients experience recurrent UTI 
(rUTI)3. In addition, the growing prevalence of UPEC strains resistant to last-line antibiotic 
treatments like fluoroquinolones, and more recently carbapenems and colistin, make UTIs a 
prime example of the current antibiotic-resistance crisis and emphasize the dire need to develop 
new approaches for treatment and prevention of bacterial infections4,5. It is widely accepted that 
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UPEC: i) establish reservoirs in the gut; ii) are shed in the feces; iii) are then able to colonize the 
peri-urethral area or vagina and subsequently ascend through the urethra to the bladder and/or 
kidneys, where they cause cystitis and/or pyelonephritis, respectively6. Chaperone-usher pathway 
(CUP) pili such as the mannose-binding type 1 pilus mediate colonization of the bladder, but 
little is known regarding the mechanisms underlying UPEC persistence in the intestinal tract. 
Single UPEC isolates can encode up to 16 distinct CUP pilus operons and each pilus type is 
thought to enable colonization of a microhabitat within a host or the environment7. In the present 
study, we use a mouse model to examine the ability of a human UPEC strain harboring nine 
different CUP operon mutants to colonize the gut. We found that both F17-like and type 1 pili 
promote intestinal colonization and show distinct binding to epithelial cells distributed along 
colonic crypts. Phylogenomic and structural analyses reveal that F17-like pili are closely related 
to pilus types carried by intestinal pathogens, but are restricted to extra-intestinal pathogenic E. 
coli (ExPEC), and have a distinct ligand specificity.  
Main Text 
Type 1 and F17-like pili promote UPEC intestinal colonization 
To examine the role of CUP pili in colonization of the gut by human UPEC strains, we 
developed a streptomycin mouse model of UPEC intestinal colonization8. We pretreated 6-week 
old female C3H/HeN and C57BL/6 mice with an oral dose of streptomycin, followed 1 day (d) 
later by an oral gavage (108 CFU) of a well-characterized human cystitis UPEC strain (UTI89) 
containing engineered chromosomal kanamycin or chloramphenicol antibiotic resistance 
markers. Sampling of feces collected 1-21 d following oral inoculation, plus surveys along the 
length of the gut conducted at the time of sacrifice, revealed that stable colonization was 
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achieved in both mouse backgrounds when they had been pretreated with streptomycin, in 
contrast to controls that did not receive antibiotic (Figure 3).  
The UTI89 genome contains 11 distinct CUP operons, 9 of which include all of the genes 
necessary to assemble a full, functional pilus. To determine if any of the 9 intact CUP operons 
promote intestinal colonization, C3H/HeN mice were co-colonized with wildtype (WT) UTI89 
and one of 9 different mutant strains, each lacking a single CUP operon. Individual deletion of 7 
CUP pilus operons yfc, yeh, yad, pap, sfa, yqi, and mat had no effect on the fitness of UTI89 in 
the gut compared to the isogenic WT strain (Figure 4a-g). However, deletion of the fim or ucl 
pilus operons, which encode type 1 and F17-like pili, respectively, resulted in significant 
colonization defects (up to 100- and 1000-fold, respectively; Figure 4h,i). Deletion of the gene 
encoding the type 1 pilus adhesin, fimH, mirrored the intestinal defect caused by deletion of the 
full type 1 pilus operon (Figure 5a). Deletion of both pilus types in a single strain produced a 
fitness defect greater than either individual deletion alone, suggesting that these two pilus types 
do not have redundant roles (Figure 4j,k). 
F17-like pili do not contribute to UTI in a mouse model of UTI 
In a mouse model, type 1-mediated binding to mannose is indispensible for bladder 
colonization and for invasion of the urothelial cells that line the bladder on its luminal side1,2. 
Once inside urothelial cells, a single bacterium can rapidly divide to form an intracellular 
bacterial community (IBC) containing 104-105 organisms1,2. Additionally, in mice that 
spontaneously resolve bacteriuria, small collections of bacteria can remain in quiescent 
intracellular reservoirs (QIRs) located within transitional bladder cells underlying the 
urothelium1,2. Bacteria from QIRs can serve to seed rUTI1,2. Numerous studies have shown 
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that mutations in fimH abolish the ability of UPEC to colonize the bladder, form IBCs and 
QIRs1,2,9.  In contrast, we found no role for the F17-like pilus in bladder colonization (Figure 
6). Both the WT and UTI89Δucl strains (i) produced similar numbers of IBCs 6 hours post 
infection (Figure 6e), (ii) had similar CFUs 28 days post infection in the urine, bladder, and 
kidneys (Figure 6b,d) and (iii) were capable of maintaining bladder-associated CFUs after 
resolution of bacteriuria, suggesting that UTI89 and UTI89Δucl are similarly capable of forming 
QIRs (Figure 6c,d). Paradoxically, one study found that genetically engineered E. coli strains 
overexpressing the ucl operon in vitro bind to desquamated epithelial cells harvested from 
human urine10.  It is possible that this paradox is explained by differences between mouse and 
human bladders or that over-expression of F17-like pili in vitro may promote binding to cells 
from a habitat where the F17-like pilus is not normally expressed in vivo. Thus, in contrast to the 
significant reduction in intestinal colonization seen for both type 1 and F17-like mutants, no role 
was observed for the F17-like pilus in the rate or severity of bladder infection in individual or 
concurrent transurethral inoculations of UTI89 and isogenic UTI89Δucl strains into the bladders 
of C3H/HeN mice. 
Type 1 and F17-like pili bind to distinct micro-habitats in the mouse colon 
Type 1 and F17-like operons each encode a two-domain tip adhesin, FimH and UclD, 
respectively. The N-terminal lectin domain of the adhesin is responsible for recognition and 
attachment to specific ligands, while the C-terminal pilin domain connects the adhesin to the 
bulk of the pilus2. We cloned and purified the lectin domains of FimH and UclD and tested their 
ability to bind to sections of mouse colon. Purified FimH lectin domain (FimHLD) bound to more 
differentiated epithelial cells located in the upper portion of crypts and in ‘surface epithelial 
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cuffs’ (the colonic homologs of small intestinal villi) (Fig. 4l). FimH binding was prevented by 
pretreatment of the tissue sections with PNGase, which cleaves N-linked oligosaccharides. This 
is consistent with known FimH specificity for mannosylated ligands since mannose is a major 
constituent of N-linked oligosaccharides (Fig 4l). FimHLD also bound to Caco-2 cells (an 
immortalized human enterocyte-like cell line derived from colorectal carcinoma) and binding 
was inhibited by both D-mannose and a high affinity mannose-analog (mannoside), M428411 
(Figure 5b). The UclD lectin domain, UclDLD, also bound to colonic epithelial cells in tissue 
sections. Binding was inhibited by pretreatment of the tissue sections with O-glycosidase, an 
enzyme that cleaves O-linked oligosaccharides, suggesting that the UclD ligand is contained 
within an O-glycan (Fig. 4m). Interestingly, FimHLD and UclDLD appeared to bind at distinct 
locations within the mouse colon; while FimHLD bound to the upper region of the crypts, UclDLD 
binding was restricted to the lower portion of crypts, suggesting that these pilus types promote 
colonization of specific niches due to binding of different carbohydrate structures expressed by 
epithelial cells at different stages of their differentiation (Fig 4l-m).  
F17-like pili are closely related to pilus types used for intestinal colonization and 
pathogenesis 
CUP pili are highly conserved throughout Proteobacteria and are assembled by dedicated 
chaperone-usher assembly machines encoded by each respective CUP operon along with the 
various subunit types comprising the pilus fiber2,7. The sequence identity between usher genes of 
distinct CUP pilus types is greater than the identity of genes that encode other CUP pilus proteins 
and thus can be compared to elucidate the evolutionary relationship of CUP pili amongst all 
proteobacterial strains7,12. Using this type of usher analysis, six large clades of pili have been 
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described. The γ clade, which is the largest, has been divided into subclades, including the γ1 
subclade containing the fim operon of E. coli, Klebsiella, and Salmonella and the γ4 clade 
containing the ucl operon7,12. To examine the evolutionary origin of F17-like pili, we performed 
a homology search of a database of γ-Proteobacterial genomes and found that the UTI89 F17-
like usher gene sequence (uclC) shared highest identity with other E. coli uclC sequences and 
with orthologous usher sequences of P. mirabilis, a bacterium that can colonize the gut, and S. 
enterica, an intestinal pathogen (Table 1). The uclC usher gene was also closely related to the 
gene encoding the F17 pilus usher (thus the derivation of the name, F17-like), as well as two 
ushers for uncharacterized pilus types, pVir99 and ECs1278 (Table 1). A phylogenetic analysis 
showed clustering of these E. coli and Proteus species’ ushers into a distinct sub-branch within 
the broader F17 group usher phylogeny, suggesting that they share a common ancestor (Figure 
7). E. coli are categorized into six distinct groups or clades of genetically related strains (clades 
A-E)10,13. F17-like pili are encoded by genes present in only 10% of all E. coli strains; these 
strains are almost exclusively in the B2 clade that harbors the majority of extraintestinal 
pathogenic E. coli (ExPEC)10. In contrast, F17 and ECs1278 pilus operons are found in the 
intestinal pathogens, enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC), 
respectively, which are specific to clades E, B1, and occasionally A14,15. These findings suggest 
that UPEC strains in clade B2 may have acquired the ucl operon from a different species and 
retained this factor to facilitate its residency in the gut. A number of genetic variants of the E. 
coli F17 adhesin, F17G, have evolved that bind different ligand variants, all containing a core N-
acetylglucosamine (GlcNAc) moiety16. No binding of UclDLD was observed to GlcNAc, either 
with the Center for Functional Glycomics glycan array or via differential scanning fluorimetry, 
indicating that the F17-like pilus binds a ligand distinct from that of the F17 pilus (Fig. 4n). 
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Interestingly, although the amino acid sequence of the full length UclD adhesin has diverged 
from that of the F17 adhesin F17G, it is virtually invariant across all strains encoding it (>99%), 
suggesting that there is a single, distinct ligand for UclD adhesins10. 
Structural analysis of the F17-like adhesin, UclD 
To examine the distribution of F17-like pili specifically in UTI isolates, a comparative 
genomic analysis was performed on 43 strains isolated from a cohort of 14 women at the time of 
initial presentation with acute UTI, or during subsequent recurrent UTIs17. Fourteen of the rUTI 
events were caused by B2 strains, which encompass the majority of E. coli strains that cause 
UTI10,13. Of these 14 strains, 13 encoded F17-like pili (~93%) (Figure 8). In contrast, F17-like 
pili have been found in less than 50% of all B2 strains10 (E. coli reference collection (ECOR)). 
We concluded that F17-like pili are enriched in B2 isolates associated with rUTI episodes in 
women from this cohort. This data, along with our findings that F17-like pili promote UPEC 
intestinal colonization, suggest that F17-like pili might be associated with UPEC persistence in 
women with rUTI due to their ability to promote maintenance of a UPEC intestinal reservoir. 
 To better understand the role of the F17-like pilus in gut colonization, we solved two high 
resolution X-ray crystal structures of UclDLD. Overlay of the structures in the P21 (green) and 
P212121 (gray) space groups resolved to 1.05 Å and 1.6 Å, respectively (Table S2) reveals they 
are nearly identical (Figure 9a-1). These structures show that nine β-strands within UclDLD 
coalesce to form an elongated β-barrel structure. Seven additional β-strands, one α-helix and two 
short 3/10 helices, that are located within inter-strand loops, comprise the remainder of the 
protein (Figure 9a-1). Comparison of the P21 UclDLD structure with the previously solved lectin 
domain structure of an F17 adhesin, F17GLD (Figure 9a-2), (PDB 1OIO18) indicates that, despite 
51 
 
a sequence identity of only 25%, the overall secondary structure characteristics are remarkably 
conserved between these two pilus types as seen when the structures are overlayed (Figure 9a-
3). Nevertheless, a structural alignment of the two lectin domains reveals two large insertions in 
UclD relative to the F17G sequence (Figure 9b; highlighted in orange and yellow). The first 
insertion is an elongation of the loop located between strands 4 and 5 and is highlighted in 
orange in Figure 9b,c. The second insertion is located between strands 8 and 9 (highlighted in 
yellow in Figure 9b,c), and contains a short 3/10 helix. Previous studies have demonstrated that 
the GlcNAc receptor binding site for the F17G adhesin is located on the side of the lectin domain 
(Figure 9a,d)16. Comparison of the UclDLD and F17GLD structures suggests the presence of a 
transverse binding site along the surface of UclDLD located in a similar position to the GlcNAc 
binding site on F17G (Figure 9a,d). This binding site, highlighted in purple in Figure 9c and by 
purple residues and stars in Figure 9b is directly adjacent to the helix-containing insertion 
located between strands 8 and 9 (colored yellow in Figure 9b,c), and located slightly above the 
elongated loop between strands 4 and 5 (colored orange in Figure 9b,c). The proximity of the 
putative binding pocket to both insertions suggests that these regions may be involved in creating 
UclD’s unique receptor binding specificity. 
The proposed UclD binding pocket is comprised of residues found in the loops 
connecting strands 6 and 7, strands 8 and 9, and within strands 2b and 9. Six key residues (Q43, 
W103, D119, N131, T134, and S136) within this pocket are denoted with stars in Figure 9b and 
shown as sticks in Figure 9d). The corresponding residues in the F17G binding site are 
chemically distinct from their UclD counterparts, (Figure 9b,d) providing further evidence to 
support our observation that UclD does not share a molecular ligand with F17G.  
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Comparison of residue positioning and electrostatic surface potential of the putative 
binding site between both UclDLD structures suggests that W103 may play a key role in the 
coordination of a sugar residue within the binding pocket, as tryptophan residues have an 
established role in aromatic-sugar stacking interactions in bacterial carbohydrate binding 
proteins19. In the P21 space group, W103 is positioned adjacent to a putative binding pocket that 
is 11 Å wide and 7 Å deep. In contrast, the P212121 structure shows well-resolved density 
indicating that the W103 side chain is flipped approximately 120 degrees, partially occluding the 
proposed binding pocket (Figure 9d). These differences may arise from differences in crystal 
packing, but may also indicate flexibility in the W103 residue that may play a regulatory role in 
ligand binding.  
Conclusions  
 Identifying the role of novel UPEC virulence factors, like type 1 and F17-like pili in gut 
colonization, revealed new mechanisms of UPEC association with its host. Specifically, 
identification of the role of F17-like pili in intestinal colonization and its relatedness to 
homologs in other bacteria that inhabit the gut provides new insights into a previously 
uncharacterized CUP pilus type. Further examination of the ligands and micro-evolution of this 
pilus type is needed to dissect the specifics of its role in gut colonization. In addition, 
identification of genes involved in UPEC colonization of the gut may also provide a method by 
which UTI patients could be stratified for epidemiologic studies of disease recurrence risk as 
well as for proof of concept clinical studies of the efficacy of CUP-directed treatment regimens. 
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Materials and Methods 
Ethics statement 
The Washington University Animal Studies Committee approved all procedures used for the 
mouse experiments described in the present study. Overall care of the animals was consistent 
with The Guide for the Care and Use of Laboratory Animals from the National Research Council 
and the USDA Animal Care Resource Guide. For collection of colonic tissues for adhesion 
binding studies, mice were sacrificed according to institutional, national and European animal 
regulations, using protocols that were also approved by the animal ethics committee of Ghent 
University. 
Bacterial strains 
CUP operon and adhesin deletions in UTI89 were engineered by replacing the gene(s) of interest 
with antibiotic-resistance markers using the λ Red Recombinase system20. Earlier reports 
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described WT UTI89 and its isogenic fim and fimH mutants21,22 as well as EC95823, 41.4p24 and 
CFT07325. 
Colonization of mice with UPEC strains 
6-week old female C3H/HeN mice were obtained from Envigo or Charles Rivers Labs (CRL). 6-
week old female C57BL/6 mice were also obtained from Envigo. Animals were maintained in a 
single room in our vivarium for no more than 2 days prior to treatment. Prior to and after 
treatment all animals received PicoLab Rodent Diet 20 (Purina) ad libitum. All animals were 
maintained under a strict light cycle (lights on at 0600h, off at 1800h). For competitive 
infections, if a phenotype was observed after testing five mice (1 biological replicate),  the 
experiment was repeated 1-2 times (total of n=10-16 mice, 2-3 biological replicates). For 16S 
rRNA analyses, 4-5 mice were examined (1 biological replicate). For all other experiments, 9-16 
mice were tested and the experiment was repeated 2-3 times (2-3 biological replicates). 
Exclusion criteria for mice were pre-established; (i) both introduced strains in competitive 
infections became undetectable during the course of a 14 day experiment, and (ii) mice died or 
lost > 20% of  their body weight. No mice in this study met these criteria. Mice were acquired 
from indicated vendors and randomly placed into cages (n=5 mice/cage) by employees of 
Washington University’s Division of Comparative Medicine (DCM); no additional methods for 
randomization were used to determine how animals were allocated to experimental groups. 
Investigators were not blinded to group allocation during experiments. 
Animals received a single dose of streptomycin (1000mg/kg in 100 µL water by oral 
gavage (PO)) followed 24 h later by an oral gavage of ∼108 CFU UPEC in 100 µl phosphate-
buffered saline (PBS). Bladder infections were performed via transurethral inoculation26. UPEC 
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strains were prepared for inoculation as described previously26. Briefly, a single UTI89 colony 
was inoculated in 20 mL of Luria Broth (LB) and incubated at 37°C under static conditions for 
24 h. Bacteria were then diluted (1:1000) into fresh LB and incubated at 37°C under static 
conditions for 18-24 h. Bacteria were subsequently washed three times with PBS and then 
concentrated to ~1x108 CFU per 100 µL for intestinal infections and ~1x108 CFU per 50 µL for 
bladder infections.  
In all cases, fecal and urine samples were collected directly from each animal at the 
indicated time points. Fecal samples were immediately weighed and homogenized in 1 mL PBS. 
Urine samples were immediately diluted 1:10 prior to plating. Mice were sacrificed via cervical 
dislocation under isofluorane anesthesia and their organs were removed and processed under 
aseptic conditions. Intestinal segments (cecum and colon) were weighed prior to homogenization 
and plating on LB supplemented with the appropriate antibiotic. 
Enumeration of bladder intracellular bacterial communities (IBCs) 
 6 week old C3H/HeN mice were given a single oral dose of either M4284 (100mg/kg) or vehicle 
control (10% cyclodextrin) 30 min before transurethral inoculation with UTI89. To accurately 
count the number of IBCs, mice were sacrificed 6 hours after infection. Bladders were removed 
aseptically, bi-sected, splayed on silicone plates and fixed in 4% (v/v) paraformaldehyde. IBCs, 
readily discernable as punctate violet spots, were quantified by LacZ staining of bladder 
wholemounts27,28.  
Immunofluorescence Studies 
 The protocols used for immunohistochemical analysis are based on a previous study29. 
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Following sacrifice of 6 week old, female C57BL/6 mice (supplied by VIB-Ghent University 
breeding program, Belgium), segments of colon were fixed in methanol-Carnoy for a minimum 
of 3 hours at room temperature. The fixed tissues were then embedded in paraffin and 4-µm-
thick sections were cut and placed on glass slides. Slides were de-paraffinized and re-hydrated 
by incubating them in xylene, isopropanol, 100% ethanol and finally 70% ethanol (each step 
involving a 3 min incubation in the reagent followed by another 3 min incubation in fresh 
reagent). Slides were subsequently rinsed in tap water and PBS, placed in blocking buffer (5% 
fecal calf serum prepared in PBS) at room temperature for 30 min, and then incubated with 
rabbit polyclonal antibodies to Muc2 [1/2000; Mucin 2 (H-300), Santa Cruz Biotechnology] for 
2 h. After three washes with PBS, slides were incubated with a goat anti-rabbit Dylight-488 
labeled secondary antibody (1/1000 dilution, ThermoFisher Cat No. 35553) in blocking buffer 
for 1 h at room temperature. Slides were washed three times with PBS before counterstaining 
with bis-benzimide (Hoechst dye) (1/1000 in PBS) for 10 min at room temperature. Finally, 
slides were incubated with FimHLD or UclDLD  (P21) protein, labeled with NHS 650nm Dylight, 
in blocking buffer at 4°C overnight. Prior to staining, sections were treated with O-glycosidase 
(NEB) or PNGaseF (SIGMA) at 37°C using buffers and protocols supplied by manufacturer . 
Slides were washed subsequently with PBS before treatment with fluoro mounting medium (n-
propyl gallate in glycerol) and viewing under a confocal microscope (Leica Microsystems LAS-
AF-TCS SP5) using a 20x125 objective.  
Carriage of F17-like pili 
We examined 43 available UPEC isolates (Table 2). These isolates originated from a clinical 
study of 14 women who experienced at least two episodes of UTI  (an initial UTI and one or 
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more rUTI) during the 90 day study window17. The isolates used in this work were sequenced in 
a previous study24 (Bioproject ID: PRJNA269984) and include (i) 14 isolates collected at 
enrollment, (ii) 18 isolates collected during rUTI (10 women experienced a single rUTI while 
four women experienced two rUTI events), and (iii) 11 isolates collected in the days leading up 
to an rUTI.  
The distribution of the F17-like operon in these clinical E. coli isolates was determined 
using BLAST and the F17-like operon from UTI89 as the query sequence. A “hit” was 
considered as any genome sequence that matched the entire length of the query sequence with 
>75% identity. As a control to prevent false negatives in the BLAST search of draft genomes, 
DNA sequencing reads from each clinical UPEC isolate were mapped against a reference 
sequence constructed by concatenating all the ucl genes with 100 N’s separators using Geneious 
v6.1.730. 
Phylogenetic Analyses and Sequence Alignments 
 Amino acid alignments of full-length UTI89 UclD, P. mirabilis UcaD, S. enterica UclH, and 
ETEC F17G were conducted using the MAFFT L-INS-i iterative refinement method and the 
default BLOSUM62 scoring matrix (Table 1)31. MAFFT collected up to 100 homologs with E 
values of less than 1e-10 to each sequence from the SwissProt database to improve alignment 
accuracy. Homologs are automatically removed from the final alignment. The alignment was 
visualized using Geneious30. A homology search of the coding sequence database of the 
European Nucleotide Archive (ENA) was conducted using the Basic Local Alignment Search 
Tool (BLAST)32 using the UTI89 uclC (ENA accession: ABE10308) and EDL933 ECs1278 
(ENA accession: AIG67653) as queries. Sequences that matched either gene sequence with 
58 
 
>50% identity were downloaded and then filtered to remove partial hits (<80% length of query 
sequence) and sequences with nonsense mutations, which resulted in a total of 659 sequences 
(Supplementary table 1). Duplicate sequences were then removed, resulting in a list of 122 
unique, representative sequences. These sequences were then aligned with the UTI89 fimD usher 
sequence (ENA accession: ABE10417) as an outgroup using the MAFFT MAFFT L-INS-i 
alignment method and the 200PAM scoring matrix31: The phylogenetic relationship between 
gene sequences was then estimated using RAxML v8.1.3 with the GTRCAT model and 
supported with 1000 bootstrap replicates; the tree was visualized using the tool interactive Tree 
of Life (iTOL) v333. 
Enzyme-linked immunosorbent assay (ELISA) targeting FimH 
 Caco-2 cells (ATCC Number HTB-37) were cultured in minimum essential medium (MEM) 
supplemented with 20% fetal bovine serum (FBS). Cell cultures tested negative for mycoplasma. 
Cells were split into 48-well plates, grown to 100% confluence and then fixed with 
paraformeldahyde for 15 min followed by treatment with blocking buffer (1x PBS containing 2% 
BSA) for 2h. A truncated FimH, corresponding to residues 1-178 of the mature FimH adhesin 
(FimHLD), expressed in E. coli  and purified as described previously34, was serially diluted in 
blocking buffer and incubated with the fixed CaCo-2 cells for 1h at room temperature. To test 
the effect of D-mannose or M4284 on FimH binding, 0.2 mg/mL FimHLD was pre-incubated for 
5 min in the presence or absence of 1 mM D-mannose (Sigma-Aldrich) or 1mM M4828 (in 20 
mM Tris pH 8.0 or 20 mM Tris plus water or 10% cyclodextrin, respectively) before serial 
dilution and incubation. Wells were washed four times with PBS/0.05% Tween 20 (PBST) prior 
to incubation with a polyclonal rabbit anti-T3 antibody against FimHLD (generated against FimH 
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residues 1-165; ref. 39) for one hour at room temperature. Following another series of four 
washes, secondary antibody (goat anti-rabbit Ig conjugated to horse radish peroxidase; 
ThermoFisher, Catalog Number 32460) was incubated with the cells for 1 h at room temperature 
(24oC) before washing in PBST. Plates were developed with the BD OptEIA TMB substrate 
reagent kit for 5 min at room temperature (24oC) before quenching with 1 M H2SO4. Binding 
was assessed by measuring the absorbance at 450 nM on a TECAN infinite 2 PRO plate reader. 
Wells lacking protein were used as control. All conditions were examined in quadruplicate. 
F17-Like Constructs and Purification 
For the P21 UclDLD construct, the first 197 amino acids of the mature UclD adhesin protein were 
cloned into pDEST14 using Gateway® technology (Invitrogen), resulting in plasmid pUclDAD. 
Expression was induced with 1mM IPTG. Periplasmic extracts were prepared by resuspending 
bacterial pellets in 20mM Tris/20% sucrose (pH 8) (4 ml/per gram of pellet). Subsequently, 40µl 
of 0.5M EDTA and 10mg/ml lysozyme were added per gram of pellet and the suspension was 
incubated on ice for 30 min. This step was followed by addition of 40 µl of 2.5M MgCl2 per 
gram of cell pellet and incubation on ice for 5 min. Cells were spun at 15,000 x g and the 
supernatant was saved as the periplasmic extract. The extract containing the UclD lectin domain 
was dialyzed against 20mM HEPES pH 7, passed over a SP FF cation exchange column (GE) 
and bound material eluted with 20mM HEPES pH7/ 1M NaCl. Pooled fractions containing UclD 
lectin domain were then applied to a Phenyl Hi Trap column (GE) after addition of 1M 
ammonium sulfate. Elution was performed using 20mM HEPES pH 7.   
To generate purified UclDLD for the P212121 space group, DNA from the UTI89 uclD 
gene encoding the N-terminal 217 amino acids of the protein were cloned into pTRC99a with a 
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C-terminal 6-His tag. This construct was expressed in the periplasm of E. coli DL41(DE3), a 
methionine auxotroph strain suitable for expression of native or selenomethionine-labeled 
protein. Periplasmic extracts were first dialyzed against PBS supplemented with 250 mM NaCl, 
then bound to a Cobalt (Goldbio) column; bound proteins were eluted with PBS containing 250 
mM NaCl, and 250 mM imidazole. Pooled fractions were dialyzed into 20 mM MES (pH 5.8), 
bound to an HR16/10 Mono S cation exchange column (GE Healthcare), and eluted with 300 
mM NaCl. Following cleavage of the periplasmic localization sequence, the mature form of 
UclDLD-6xHis contained 203 amino acids.  
Selenomethionine-labeled protein was purified using the same protocol, but all buffers 
were supplemented with 2 mM β-mercaptoethanol  and 1 mM EDTA to prevent oxidation. 
EDTA was omitted from the periplasmic dialysis buffer to prevent chelation of immobilized 
cobalt.  
Crystallization and Structure Determination 
 For the P21 UclDLD structure solved in the P21 space group, UclDLD
 (15mg/ml) was crystallized 
using sitting drop vapor diffusion against a solution containing 16% PEG 4000, 0.1M Tris HCl 
pH 8.5, 0.2M magnesium chloride. UclD crystals were flash cooled to 100oK in a solution 
containing 16% PEG 4000, 0.1M Tris HCl pH 8.5, 0.2M magnesium chloride and 30% glycerol. 
Data were collected at beamline ID29 (ESRF, Grenoble, France) to 1.05 Å resolution. Data were 
indexed and processed with XDS35, scaled and merged using SCALA in the CCP4 suite36. Data 
and refinement statistics can be found in Table 3.  
For the UclDLD structure solved in the P212121 space group, UclDLD (10 mg/ml 10 mM 
MES 5.8) was crystallized by the hanging drop vapor diffusion method against a well solution 
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containing 0.1 M potassium phosphate (monobasic), 0.2 M potassium iodide and 20% PEG 
3350. One microliter of the protein solution was mixed with 1 µL well solution and incubated at 
18 °C. Crystals were harvested and transferred to a solution containing 0.1 M KH2PO4, 0.2 M KI 
and 20% PEG 3350 supplemented with 20% glycerol before being flash-frozen in a bath of 
liquid N2. Data were collected at beamline 4.2.2 (ALS Berkeley) to 1.6 Å resolution. Data were 
indexed and processed with XDS35, scaled and merged AIMLESS in the CCP4 suite36 and 
phased with the Single anomalous dispersion (SAD) method using phenix.autosol, and refined 
with phenix.refine37. Data and refinement statistics can be found in Table 3. RMSD values were 
calculating using the DALI server38. Structural alignments were performed in Promal’s 3D using 
the default settings. Secondary structure assignments for UclDLD were completed using DSSP.  
Differential Scanning Fluorimetry 
 Purified UclDLD (1.4 mg/well) was incubated with 5x Sypro orange fluorescent dye in 20 mM 
Tris (pH 8.0) with or without 10 mM monosaccharide in a total volume of 70 µL. Samples were 
heated from 20 °C to 100 °C in 30-second/0.5 °C increments using a Bio-rad C1000 
thermocycler with CFX96 RT-PCR attachment. The reported melting temperatures were 
determined by the inflection point of the sigmoidal graph.  
Data Availability 
Sequences used to examine the carriage of F17-like pili in clinical rUTI isolates were previously 
published24 and are deposited in the NCBI under the Bioproject ID: PRJNA269984. 
Crystallography data have been deposited in the PDB under accession codes: 5NWP (P21) and 
5VQ5 (P212121). 
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Statistical Analysis 
The statistical significance of differences between groups in experiments (excluding competitive 
infections) was determined by a Mann Whitney U test. Competitive Index (CI) was defined as 
(CFU output strain A/CFU output strain B)/(CFU input strain A/CFU input strain B). For 
competitive infections, statistical significance was determined by a Wilcoxon Signed Ranked 
test. Statistical analyses were performed using Graphpad Prism 7.  
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Figures 
 
Figure 3. Streptomycin treatment allows for persistent UTI89 colonization of the intestine 
in female C3H/HeN and C57BL/6 mice. (a) Mice were pretreated with streptomycin and 
subsequently colonized via oral gavage (PO) with UTI89, a prototypical human UPEC cystitis 
isolate. (b-e) Colonization of UTI89 in C3H/HeN mice from Envigo (panels b,c) or C57BL/6 
mice from Envigo (panels d,e) was assessed by quantifying colony forming units (CFU) in fecal 
samples collected over the course of 21 days from mice who did not receive streptomycin (white 
circles) or mice pretreated with the antibiotic (black circles). CFU analysis of levels of 
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colonization in the cecum and colon were defined by analyzing tissue homogenates prepared 21 
days post colonization. Symbols represent geometric means ± SD, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 (Mann Whitney U test). n=15 mice, 3 replicates (panels b-e). 
 
 
Figure 4. Type 1 and F17-like pili promote UPEC intestinal colonization. (a-i) C3H/HeN 
mice were treated with streptomycin and concurrently colonized with 1x108 CFU of Wildtype 
(WT) UTI89 and one of 9 CUP operon knockout strains. (a-g) Deletion of 7 CUP operons had no 
impact on the fitness of UTI89. (h,i) Loss of operons that encode type 1 and F17-like pili (fim 
and ucl operons, respectively) decreased fitness compared to the WT strain. (j) Deletion of the 
fim and ucl operons in a single strain produced a fitness defect greater than deletion of each pilus 
alone. (k) Strains lacking either or both pilus operons also had fitness defects at 4 days post 
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gavage when singly-colonized. (l,m) Purified adhesin lectin domains for the type 1 and F17-like 
pilus (FimHLD and UclDLD, respectively) were tested for binding to mouse colonic sections. 
Sections were stained with Hoechst (blue) and rabbit antibodies to Muc2, a prominent mucus-
associated glycoprotein (green). Purified FimHLD binds to epithelial cells positioned in the upper 
half of crypts and surface epithelial cuffs. FimHLD binding is lost by pre-treatment of sections 
with PNGase (compare top and bottom images in panel l). UclDLD binds to epithelial cells 
located in the lower half of crypts. Binding is inhibited by pretreatment of sections with O-
glycosidase (compare top and bottom images in panel m). To the right of the overview images in 
panels l and m, we show higher power views of individual crypts. Arrowheads point to examples 
of sites of binding of the purified adhesins. (n) The absence of a shift in the melting temperature 
of UclDLD in the presence of five monosaccharides tested using differential scanning 
fluorimnetry suggests that none of these sugars bind UclDLD in solution. In contrast, FimHLD 
binds monomannose with high affinity, resulting in a mean melting temperature shift of ~11°C. 
Abbreviations. Ce= cecum, Col= colon. CI= competitive index. Bars represent mean values ± 
SEM in  panels a-j, n and geometric means ± SD in panel k. *p<0.05, **p<0.01, ***p<0.001 by 
Wilcoxon Signed Ranked test (panels a-j) or Mann Whitney U test (panel k). n=5 mice, 1 
replicate (panels a, d-g), n=6 mice, 1 replicate (panel c); n=9, 2 replicates (panel j); n= 10 mice, 2 
replicates (panels b,h) n=15 mice, 3 replicates (panels i,k). 
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Figure 5. The FimH adhesin is required for type 1 pilus-dependent colonization of the 
mouse gut and for binding to human intestinal epithelial cells. (a) C3H/HeN mice from 
Envigo were pretreated with streptomycin and colonized with 1x108 CFU of WT UTI89 and 
UTI89ΔfimH. The WT strain is able to outcompete the strain lacking the FimH adhesin. (b) The 
ability of purified FimH lectin domain (FimHLD) to bind to Caco-2 cells was assessed by FimH-
ELISA. Pre-incubation of FimHLD with a 50-fold excess of D-mannose (5mM) or M4284 (5mM) 
results in significant reductions in FimH binding to the Caco-2 cells while 10% cyclodextrin 
(M4284 vehicle) alone had no significant effect. All data shown are normalized to wells that 
were not exposed to the purified adhesin. Abbreviations CI= competitive index. Ce= cecum, 
Col= colon. Bars represent mean values ± SEM, *p<0.05, **p<0.01, ***p<0.001 (Wilcoxon 
Signed Ranked test) in panel a. Bars represent mean ± SEM, *p<0.05 (Mann Whitney U test) in 
panel b. n=14 mice, 3 replicates (panel a); n=4 replicates/treatment (panel b). 
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Figure 6. F17-like pili are not required for UTI in mice. C3H/HeN mice received a 
transurethral inoculation of UTI89 (WT) and UTI89Δucl, concurrently (a, b), or individually (c-
e). (a) UTI89Δucl and WT strains persist at similar levels in the urine over 28 d in competitive 
infections. (b) The two strains are also present at equal levels in the bladder and kidney at the 
time of sacrifice 28 days post infection. (c) Single infection with the WT strain (black circles) or 
the F17-like mutant strain (white circles) produces similar levels of bacteruria over 28 days. (d) 
Single strain infection also produces similar levels of viable cells in homogenates of whole 
bladder or kidneys harvested at the time of sacrifice (28dpi). There was no statistically 
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significant difference in the number of mice that resolved bacteriuria while maintaining bladder-
associated CFUs after transurethral infection with either WT or UTI89Δucl (highlighted in red in 
panel d), suggesting that both of these strains are capable of forming similar numbers of QIRs. 
(e) Mice infected transurethrally with WT or UTI89Δucl formed a similar number of intracellular 
bacterial communities (IBCs) at 6 hours in the bladder, indicating that loss of the ucl operon does 
not alter UTI89’s ability to form IBCs. CI= competitive index. Bars represent mean ± SEM 
(panels a,b), geometric mean (panels c,d) or median (e). No significant difference was detected 
between any samples by Wilcoxon Signed Ranked test (panels a,b) or Mann Whitney U test 
(panels c-e). n=10 mice, 2 replicates (panels a-b, e). n=16 mice, 3 replicates (panels c-d).  
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Figure 7. Distribution of F17 usher homologs in Enterobacteriaceae. The phylogenetic 
relationships between F17 homologs was estimated using the sequence of the usher genes. 
Branch colors indicate host strain and pilus identity, while colored symbols indicate the 
annotated pathotype of the E. coli strain for each sequence as determined by publically available 
annotations. Stars indicate extraintestinal pathogenic E. coli (ExPEC) strains while circles 
indicate intestinal pathogenic E. coli strains. Carriage of F17-like pili is enriched in UPEC strains 
while F17 and ECs1278 pili are more common in intestinal pathogens such as EHEC. The strain 
names for each sequence and ENA accession IDs are given. Numbers beneath the branches 
indicate the percentage of support from 1000 bootstrap replicates (numbers greater than 80% are 
shown).  
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Figure 8. Phylogenetic distribution of F17-like carriage in UPEC from patients with 
rUTI. The phylogeny of a set of clinical UPEC strains (n=43 with taxon labels highlighted in 
green, orange, or grey) was contextualized with reference E. coli strains (n=46, unhighlighted 
taxon labels) by comparing the concatenated single-copy, core genes of the strains using the 
RAxML algorithm and the GTRCAT model39. Highlighted taxon labels indicate UPEC isolates 
collected at enrollment (green) and during recurrent UTI (orange).  In all cases, patients cleared 
each infection prior to recurrence, no patient exhibited signs of asymptomatic bacteriuria. The 
study design also allowed for the collection, from cohort participants, of E. coli isolates present 
in the urine in the days leading up to their clinical visit and rUTI diagnosis (highlighted in grey), 
as described previously17. Branch lines indicate phylogenetic background for strains from clade 
B2 (red branch lines) and non-B2 clades (blue branch lines). Carriage of F17-like pili (black 
stars) was limited to the B2 clade and enriched within rUTI UPEC isolates. Bootstrap supports 
are indicated at internal nodes. Bootstrap values >95 have been removed. The clade to which 
each strain belongs is indicated in brackets to the right. 
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Figure 9. Structural analysis of UclDLD. (a) Comparison of the structures of UclDLD and 
F17GLD. Superposition of the P21 UclDLD (green) P212121 UclDLD (grey) crystal structures (a-1). 
Crystal structure of the F17G adhesin (PDB 1OIO18) (a-2). Superposition of the P21 
UclDLD (green) and F17GLD (cyan) crystal structures (a-3). Despite a primary sequence identity 
of only 25%, the structures superimpose with an Cα root mean square deviation of of 2.7 Å. (b) 
Structural alignment of the UclDLD and F17GLD amino acid sequences using the PROMALS3D 
server. All 16 regions assigned as β-strands by the Dictionary of Secondary Structure of Proteins 
(DSSP)40 are conserved in both proteins despite low sequence identities. UclD residues 
highlighted in purple are postulated to contribute to binding of a small core ligand, 
while surrounding residues highlighted in yellow and orange may bind to different moieties on a 
larger molecular receptor. Starred residues are represented as sticks in panel d. (c) Surface 
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representation of the UclDLD structure, with key regions of divergence highlighted in yellow, 
orange, and purple according to the representation in panel b. (d) Comparison of residue 
positioning and electrostatic surface potential of the putative binding site between the two 
UclDLD structures and the known binding site of the F17GLD structure. We believe that the side 
chain and/or backbone positions of Q43, W103, D119, N131, T134, and S136, shown here in the 
stick representation, likely coordinate binding to a glycan-containing sugar residue in the 
putative binding pocket. The residues occupying the analogous positions on F17G are also 
shown as sticks. 
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Chapter 3: Selective depletion of uropathogenic 
E. coli from the gut by a FimH antagonist 
Adapted from: 
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist 
Caitlin N. Spaulding, Roger D. Klein, Ségolène Ruer, Andrew L. Kau, Henry L. 
Schreiber IV, Zachary T. Cusumano, Karen W. Dodson, Jerome S. Pinkner, Daved H. 
Fremont, James W. Janetka, Han Remaut, Jeffrey I. Gordon, Scott J. Hultgren 
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Abstract 
 UTIs are a major contributor to global antibiotic use. In the United States alone, 9% of all 
antibiotics prescribed in a year are for the treatment of UTIs 1. The global prevalence of single 
and multi-drug resistant UPEC isolates highlights our reliance on antibiotics to treat these 
infections and stresses the need to develop alternative treatments to combat resistant pathogens. 
However, the development and spread of antibiotic resistance is not the only issue with our 
current method of treatment. An increasing number of published papers are finding that 
disruption of the gut microbiota by orally administered antibiotics, especially during childhood, 
81 
 
may affect its functional properties in ways that are deleterious to the host, not only in the short 
term but for more protracted periods of time if the antibiotic perturbation is not followed by 
adequate restoration of the community 2,3. Therefore, developing treatments for pathogens, like 
UPEC, that can specifically target a pathogen without damaging the remainder of the microbial 
community is important. This ‘molecular-scalpel’ approach to drug development is increasing in 
scope. Treatment with mannoside has recently been shown to target the intestinal population of 
AIEC in a transgenic mouse model 4. The identification of a selective therapy that is designed to 
target staphylococci spp. but has minimal other effects on the microbiota has shown that this type 
of treatment is possible 5. Another study found that a cocktail of bacteriophages could target 
UPEC in the gut with minimal impact on the overall composition of the microbiota; however, the 
translatability of these types treatment to a wide-range of uropathogens and in hosts with 
different genetics and microbial compositions is unknown 6.  
 My finding that type 1 pili promote UPEC intestinal colonization, outlined in Chapter 2, 
provided an exciting and unique opportunity determine if an anti-adhesive therapeutic could 
provide an alternative, and potentially antibiotic sparing, method to removing UPEC from the 
host. The essentiality of the FimH-mannose interaction during UTI prompted the design and 
development of orally active, synthetic, small-molecule inhibitors of FimH called mannosides, 
which are mannose analogs that are rationally designed to bind within the mannose-binding 
pocket of FimH with a high affinity 7. Therefore, I tested the ability of oral mannoside treatment 
to target UPEC in both the gut and bladder. My findings show that mannoside treatment 
successfully targets a pilus type that is importance for intestinal colonization in mice and 
humans. This treatment targets a range of UPEC strains and is successful regardless of host 
genetics or microbiota composition. This treatment specifically targets UPEC while leaving the 
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surrounding microbiota uninjured and can simultaneously target UPEC in the gut reservoir and at 
the site of infection.  
 Aside from providing a much-needed method to treat individuals infected with drug 
resistant uropathogens, a selective treatment, like mannosides, would also reduce the exposure of 
entire gut microbiota to antibiotics and thus could curb the development of antibiotic resistant 
pathogens. Due to their prevalence worldwide, UTIs are and will continue to be a major 
contributor to antibiotic use and resistance. Unfortunately, high rates of UTI and rUTI worldwide 
have provided almost persistent exposure of uropathogens to antibiotics, resulting in the 
development and swift expansion of UPEC strains encoding resistance genes to one or more 
classes of antibiotics. Without effective antibiotics active against uropathogens, UTIs, which are 
typically considered low risk infections, will become life threatening and many urological 
procedures will carry excessive risk. The need to develop alternative, antibiotic-sparing therapies 
to treat individuals with UTI is obvious and pressing.  
Main Text 
Mannosides target and reduce type 1-expressing UPEC in the gut reservoir   
As outlined in Chapter 2, FimH and UclD promote gut colonization and epithelial cell 
binding by UTI89. Therefore I conducted a proof-of-concept study designed to eliminate the 
UPEC intestinal reservoir in this mouse model using a candidate adhesin-directed therapeutic. 
M4284 is a high affinity biphenyl mannoside that inhibits FimH binding to Caco-2 cells (Figure 
5). M4284 has a binding affinity for FimH that is ~100,000-fold higher than the natural sugar D-
mannose7,8. Pharmacokinetic (PK) analysis showed that after a single oral gavage, M4284 
remains present at high concentration in the feces of recipient mice for up to 8 hours (h) (Figure 
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10a). In a follow-up experiment, mice were treated with streptomycin, orally gavaged with 
UTI89 24 h later, and 3 d later given 3 doses of M4284 (100mg/kg) over a 24 h period (Figure 
10b). This dosing regimen was previously used to successfully treat UPEC infection of the 
mouse bladder with mannoside9-11. Treatment with M4284 significantly reduced levels of UTI89 
in feces as well as cecum and colon by up to 1.5 logs (98% reduction) (Figure 10c). Treating 
mice with up to 5 oral doses of M4284 (3 doses administered over 24 h followed by two 
additional doses given over the remaining 48 h) reduced the UTI89 population to an even greater 
extent (up to 1000-fold) (Figure 11a,b). Moreover, the overall number of UPEC continued to be 
lower in mannoside-treated mice up to 5 days after termination of treatment (Figure 11c,d). 
While D-mannose blocks FimH binding in vitro at high concentrations (Figure 5), treating mice 
with D-mannose had no effect on UTI89 titers in the cecum, colon, and feces (Figure 10d). 
Thus, unlike D-mannose, M4284 can effectively compete with the natural receptor at nanomolar 
concentrations and prevent FimH-mediated host-pathogen interactions. 
Mannosides simultaneously target UPEC in the gut and bladder   
There is no mouse model of spontaneous UTI. Moreover, the proximity of the mouse 
urethra to soiled bedding and the coprophagic behavior of these animals make creating such a 
model challenging. Thus, there is no direct way to test how reducing the UPEC intestinal 
reservoir would alter the rate of UTI. However, the established ID50, or minimum number of 
UPEC that result in a 50% infection rate in the mouse model of UTI, is 105 CFU12. Decreasing 
the inoculation dose of UPEC introduced into the bladder from 108 to 106 CFU resulted in 
significantly reduced rates of UTI (Figure 12) suggesting that the 1-1.5 log (or 90-95%) 
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mannoside-driven reduction in fecal UPEC levels would reduce the numbers of bacteria 
available to be inoculated into the urinary tract and likely reduce the rate of UTI and/or rUTI.  
 M4284 has low oral bioavailability (<2 %). Thus, >98% of the drug is not absorbed into 
the systemic circulation, allowing the compound to exert its effects on type 1-expressing UPEC 
in the gut but potentially limiting its effectiveness in the bladder7. To assess whether M4284 
could treat an active infection in the bladder while simultaneously reducing the intestinal UPEC 
reservoir, mice were orally gavaged with UTI89 and 24 h later given a UTI via transurethral 
inoculation. Two days after inoculation of UTI89, 3 doses of M4284 were administered orally 
over a 24 h period. Animals were sacrificed 8 h after the last dose and colonization was assessed 
(Figure 10e). M4284 significantly reduced UTI89 titers throughout the length of the distal gut 
(up to 98%) and in the urinary tract (96-99%) (Figure 10f,g), demonstrating that this mannoside 
has sufficient oral absorption to exert its effect in the bladder.  
Oral mannoside treatment has minimal effects of the structure of the gut microbiota  
 To determine whether mannoside treatment affects the gut microbiota structure, we 
treated C3H/HeN mice that had not been given streptomycin or infected with UPEC with 3 doses 
of M4284 or vehicle alone (10% cyclodextrin). Sequencing bacterial 16S rRNA gene amplicons 
generated from fecal samples collected 24 h after cessation of treatment revealed that M4284 
produced no significant changes in the overall phylogenetic configuration of the microbiota as 
judged by the unweighted UniFrac dissimilarity metric, in contrast to the significant 
perturbations produced by treatment with ciprofloxacin, a fluoroquinolone antibiotic (Figure 
13a,b, Figure 14a,b). Using this same metric, we found that M4284 treatment did not produce 
significant perturbations in bacterial community structure in mice pretreated with streptomycin 
85 
 
and then colonized with UTI89 (Figure 15). We concluded that M4284 can function to 
selectively extirpate UPEC from the gut in our preclinical model. Interestingly, the operon 
encoding type 1 pili is carried by nearly every sequenced E. coli strain13 and is highly conserved 
throughout the family Enterobacteriaceae14. However, we found that M4284 treatment has no 
significant effect on the abundance of Enterobacteriaceae (Figure 14a,b), suggesting that these 
bacteria may not be expressing type 1 pili during M4284 exposure or that they reside within 
inaccessible intestinal habitats, like biofilms, and are therefore not greatly affected by 
mannoside treatment. Further examination of the effects of M4284 treatment on gut 
colonization by different species/strains of Enterobacteriaceae is needed to more fully interpret 
the significance of these findings. 
Mannoside treatment decreases gut colonization by genetically diverse UPEC clinical 
isolates  
 Clinical isolates of UPEC strains are genetically diverse, differing significantly in their 
carriage of different pathogenicity associated islands, CUP pili, and resistances to commonly-
used antibiotics. Only 60-75% of each UPEC strain’s genome is comprised of a set of shared 
genes; fimH is part of this core genome. Therefore, we examined the efficacy of M4284 against a 
panel of four diverse UPEC clinical isolates, UTI89, CFT073, EC958, and 41.4p. These isolates 
reflect some of the genetic diversity of UPEC; UTI89, EC958, and CFT073 belong to clade B2, 
while 41.4p is a member of clade B1. UTI89, EC958, and 41.4p are cystitis isolates, while 
CFT073 is a urosepsis isolate. EC958 also encodes resistance genes to a number of clinically 
relevant antibiotics. We were able to establish and maintain intestinal colonization of our mouse 
model with each isolate tested, and found that M4284 treatment produced similar, statistically 
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significant reductions in the levels of each UPEC strain in the cecum, colon, and feces (Figure 
13b-f). In each case, the percent reduction in feces or cecum/colon was similar (Figure 16a). 
Mannoside treatment reduces UTI89 intestinal colonization in mice of different genetic 
backgrounds with diverse gut microbiota communities 
Since UTI and rUTI occur in individuals of diverse genetic backgrounds and varied gut 
microbiota configurations, we also tested the efficacy of M4284 in both C3H/HeN and C57Bl/6 
mice, each from different vendors with different gut microbial community configurations (e.g. 
Figure 14c). We found that this treatment reduced the UTI89 intestinal reservoir in each case 
tested, with the percentage of UPEC removed from the feces, cecum, and colon not varying 
significantly between the three groups of mice (Figure 14f-h, Figure 16b). From these results, 
we concluded that M4284 treatment has activity against different UPEC strains in different host 
genetic backgrounds and gut microbial community contexts.  
Conclusions 
 As the prevalence of antibiotic-resistant pathogens continues to rise, the need to develop 
highly targeted/specific therapeutic approaches has gained increased urgency5,6. Additionally, an 
increasing number of studies are finding that disruption of the gut microbiota by orally 
administered antibiotics, especially during childhood, may affect its functional properties in 
ways that are deleterious to the host, not only in the short term but for more protracted periods of 
time2,3. Therefore, developing therapeutic agents, like mannosides, that can specifically target a 
pathogen without disrupting the remainder of a microbial community has important ramifications 
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not only for UPEC but potentially for other infections, including those caused by 
enteropathogens.   
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Materials and Methods 
Ethics statement 
The Washington University Animal Studies Committee approved all procedures used for the 
mouse experiments described in the present study. Overall care of the animals was consistent 
with The Guide for the Care and Use of Laboratory Animals from the National Research Council 
and the USDA Animal Care Resource Guide. For collection of colonic tissues for adhesion 
binding studies, mice were sacrificed according to institutional, national and European animal 
regulations, using protocols that were also approved by the animal ethics committee of Ghent 
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University. 
Bacterial strains 
CUP operon and adhesin deletions in UTI89 were engineered by replacing the gene(s) of interest 
with antibiotic-resistance markers using the λ Red Recombinase system15. Earlier reports 
described WT UTI89 and its isogenic fim and fimH mutants12,16 as well as EC95817, 41.4p18 and 
CFT07319. 
Colonization of mice with UPEC strains 
6-week old female C3H/HeN mice were obtained from Envigo or Charles Rivers Labs (CRL). 6-
week old female C57BL/6 mice were also obtained from Envigo. Animals were maintained in a 
single room in our vivarium for no more than 2 days prior to treatment. Prior to and after 
treatment all animals received PicoLab Rodent Diet 20 (Purina) ad libitum. All animals were 
maintained under a strict light cycle (lights on at 0600h, off at 1800h). For competitive 
infections, if a phenotype was observed after testing five mice (1 biological replicate),  the 
experiment was repeated 1-2 times (total of n=10-16 mice, 2-3 biological replicates). For 16S 
rRNA analyses, 4-5 mice were examined (1 biological replicate). For all other experiments, 9-16 
mice were tested and the experiment was repeated 2-3 times (2-3 biological replicates). 
Exclusion criteria for mice were pre-established; (i) both introduced strains in competitive 
infections became undetectable during the course of a 14 day experiment, and (ii) mice died or 
lost > 20% of  their body weight. No mice in this study met these criteria. Mice were acquired 
from indicated vendors and randomly placed into cages (n=5 mice/cage) by employees of 
Washington University’s Division of Comparative Medicine (DCM); no additional methods for 
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randomization were used to determine how animals were allocated to experimental groups. 
Investigators were not blinded to group allocation during experiments. 
Animals received a single dose of streptomycin (1000mg/kg in 100 µL water by oral 
gavage (PO)) followed 24 h later by an oral gavage of ∼108 CFU UPEC in 100 µl phosphate-
buffered saline (PBS). Bladder infections were performed via transurethral inoculation20. UPEC 
strains were prepared for inoculation as described previously20. Briefly, a single UTI89 colony 
was inoculated in 20 mL of Luria Broth (LB) and incubated at 37°C under static conditions for 
24 h. Bacteria were then diluted (1:1000) into fresh LB and incubated at 37°C under static 
conditions for 18-24 h. Bacteria were subsequently washed three times with PBS and then 
concentrated to ~1x108 CFU per 100 µL for intestinal infections and ~1x108 CFU per 50 µL for 
bladder infections.  
In all cases, fecal and urine samples were collected directly from each animal at the 
indicated time points. Fecal samples were immediately weighed and homogenized in 1 mL PBS. 
Urine samples were immediately diluted 1:10 prior to plating. Mice were sacrificed via cervical 
dislocation under isofluorane anesthesia and their organs were removed and processed under 
aseptic conditions. Intestinal segments (cecum and colon) were weighed prior to homogenization 
and plating on LB supplemented with the appropriate antibiotic. 
Mannoside Treatment 
D-mannose or the mannoside M4284 (which has been characterized in a prior published study11), 
were diluted in vehicle (water and 10% cyclodextrin, respectively) and administered to 6 week 
old C3H/HeN mice at a dose of 100mg/kg. Control animals were treated with water or 10% 
cyclodextrin alone. Unless stated otherwise, three doses of M4284, cyclodextrin, or D-mannose 
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were given via oral gavage over 24 hours, with doses administered 8 h apart. Mice were 
sacrificed and intestinal tissues were processed for analysis of viable bacteria (CFU) 8 h after the 
last dose, unless otherwise noted. To test the effect of M4284 on intestinal UPEC titers after 
treatment was terminated, mice were sacrificed 5 days after the last dose of mannoside. To test 
the effect of additional doses on M4284 treatment on UPEC titers, mice were given 5 doses of 
mannoside; the first 3 doses were administered 8 h apart, followed 12h later by the 4th dose, and 
24h later by the 5th dose. Mice were sacrificed 24h after the 5th dose.  
Effect of antibiotic exposure on the microbiota 
Six week old female C3H/HeN mice from Envigo and CRL were subjected to the following 
treatments: (i) none (naïve control mice, Untreated), (ii) three doses of M4284 (100mg/kg; in 
10% cyclodextrin) or 10% cyclodextrin given 8 h apart, or (iii) ciprofloxacin (two doses of 
15mg/kg given 12 h apart). All doses were given via oral gavage. Five mice were included for 
each treatment type (1 biological replicate) and fecal samples were collected prior to treatment 
and 24 hours after the last dose of each treatment. Another group of four C3H/HeN mice from 
Envigo (1 biological replicate) were pretreated with streptomycin and colonized with UTI89 
before recieving treatment with either three doses of M4284 (100mg/kg; in 10% cyclodextrin) or 
with 10% cyclodextrin alone;  fecal samples were collected prior to treatment but after exposure 
to streptomycin and UTI89 and 24 hours after the last dose of each treatment. 
Bacterial 16S rRNA sequencing 
 DNA was extracted by bead beating in extraction buffer [200 mM Tris (pH 8.0), 200 mM NaCl, 
20 mM EDTA], 210µL of 20% SDS and 500µL phenol:chloroform:isoamyl alcohol (pH 7.9, 
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25:24:1). This crude DNA extract was purified (Qiaquick PCR purification kit) and PCR used to 
generate amplicons from the V4 region of bacterial 16S rRNA genes using primers and cycling 
conditions described previously21. Amplicons were pooled in equimolar ratios and sequenced on 
an Illumina MiSeq instrument (paired end 250 nt reads). Paired V4-16S rRNA sequences were 
merged using FLASH software22, demultiplexed, and reads clustered into 97%ID OTUs (2013 
Greengenes OTU reference database; QIIME version 1.9.023). A custom database using modified 
NCBI bacterial taxonomy was used to train the Ribosomal Database Project (RDP) version 2.4 
classifier and assign taxonomy to picked OTUs24. The resulting OTU table was filtered to 
include only OTUs found in at least two samples at greater than or equal to 0.1% relative 
abundance. 
Data Availability 
 Bacterial V4-16S rRNA datasets have been deposited in the European Nucleotide Archive 
(ENA) under accession number PRJEB19121.  
Code Availability 
No new code was generated for this study. All software was obtained from publicly available 
sources; papers describing the software are cited in the text.   
Statistical Analysis 
 The statistical significance of differences between groups in experiments (excluding competitive 
infections) was determined by a Mann Whitney U test. Competitive Index (CI) was defined as 
(CFU output strain A/CFU output strain B)/(CFU input strain A/CFU input strain B). For 
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competitive infections, statistical significance was determined by a Wilcoxon Signed Ranked 
test. Statistical analyses were performed using Graphpad Prism 7.  
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Figures 
 
Figure 10. Mannoside simultaneously reduces the UPEC intestinal reservoir and treats 
UTI. (a) The concentration of M4284 in the feces of mice remains higher than the EC90 of the 
drug after a single, oral dose of 100mg/kg. (b) To test the efficacy of M4284 to target UTI89 in 
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the mouse intestine, mice were pretreated with streptomycin and colonized with UTI89. Starting 
at 3 days post colonization (dpc), mice were given 3 oral doses of M4284 (100mg/kg) or 10% 
cyclodextrin (control). (c) UTI89 levels in the feces and intestinal segments were assessed 8 h 
after the last dose of mannoside. (d) While mannoside treatment reduced the UTI89 intestinal 
load, treatment with D-mannose did not. (e) To determine if M4284 treatment can 
simultaneously treat an active UTI and target UPEC in the gut, mice were pretreated with 
streptomycin and then received an oral gavage of UTI89. One day later, they were given a UTI 
via a transurethral inoculation of this uropathogen. Two days later, they received 3 oral doses of 
M4284 (100mg/kg). M4284 reduces UTI89 titers in the gut (f) and urinary tract (g). Bars 
represent mean± SEM (a), geometric means ± SD (c,d,f), geometric mean (g) *p<0.05, **p<0.01 
by Mann Whitney U test. n=9 mice, 2 replicates (panels f, g), n= 10 mice, 2 replicates (panel d) 
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Figure 11. Testing the effects of more prolonged dosing of M4284 and analysis of the 
duration of its effects. (a) C3H/HeN mice from Envigo were given two additional doses of 
M4284 (5 doses total). (b) Animals treated as in panel (a) show a continued decrease in UTI89 
levels in their feces (fecal samples were processed after 3, 4, and 5 doses of M4284), and at the 
time of sacrifice in the cecum and colon, compared to control mice treated with vehicle alone 
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(10% cyclodextrin). (c,d) The effects of mannoside treatment persist out to 5 days post M4284 
exposure. Bars represent geometric mean ± SD, *p<0.05, **p<0.01 by Mann Whitney, n=9-10, 2 
replicates (panel b), n=16 mice, 3 replicates (panel d). 
 
 
 
Figure 12. The severity of UTI outcome is directly linked to the dose of UTI89 inoculated 
into the urinary tract. C3H/HeN mice (Envigo) were given an experimental UTI via 
transurethral inoculation of either 108  or 106 CFU of UTI89. The doses were chosen to represent 
the reduction observed in intestinal UTI89 titers before and after treatment with the M4284 
mannoside. Mice were sacrificed 24 hours after inoculation and UTI89 titers in urine, bladder, 
and kidneys were defined by quantifying CFU. Mice receiving the 106 dose of UTI89 had 
significantly fewer bacteria in all three biospecimen types, indicating an important relationship 
between the number of bacteria introduced into the urinary tract and the severity of UTI 
outcome. Bars represent geometric means, **p<0.01, ***p<0.001, ****p<0.0001 by Mann 
Whitney U test. n=10 mice, 2 replicates. 
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Figure 13. Mannoside treatment has minimal effect on the overall configuration of the fecal 
microbiota and targets different human UPEC isolates in mice with different genetic 
backgrounds.  Mice were given one of the following treatments: (i) M4284 (100mg/kg; 3 doses 
over 24 h), (ii) cyclodextrin (10%, Cyclo; 3 doses over 24 h); or (iii) ciprofloxacin (Cipro; 
15mg/kg; 2 doses over 24 h). Naïve, untreated mice served as controls (Untreated). Fecal 
community structure was defined by sequencing bacterial 16S rRNA gene amplicons. (a) For 
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each treatment performed on C3H/HeN mice obtained from Envigo and Charles Rivers Labs, the 
change in microbiota configuration was determined by measuring the unweighted UniFrac 
distance between samples obtained from each mouse before treatment and 24 h after they 
received their last dose (larger UniFrac distance equates to a larger shift in community structure 
(beta diversity)). (b) Mice of different genetic backgrounds were colonized by oral gavage with 
one of 4 different UPEC strains. At 3 dpc, mice were given 3 doses of M4284 and sacrificed 8 h 
after the last dose. (c-f) The intestinal tracts of C3H/HeN mice from Envigo labs were colonized 
by each of the genetically diverse human UPEC isolates. (g,h) The ability of M4284 to target 
UTI89 in C3H/HeN mice from Charles Rivers Labs (CRL) (panel g) and C57BL/6 mice from 
Envigo Labs (panel h) was also assessed. bar = median value. *p<0.05, **p<0.01 (Mann 
Whitney U test). n=5 mice, 1 replicate (panel a). Bars represent geometric means ± SD, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 (Mann Whitney U test) (panels c-h). n=9-10 animals, 2 
replicates (panels c-e, g-h); n=14-15 mice, 3 replicates (panel f) 
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Figure 14. 16S rRNA-based comparison of fecal bacterial communities in mice obtained 
from Envigo and Charles Rivers Labs and mice of different genetic backgrounds from a 
common vendor. (a) C3H/HeN mice were treated with M4284 (100mg/kg, 3 doses over 24 h), 
vehicle alone (10% cyclodextrin (Cyclo), 3 doses over 24 h), or ciprofloxacin (Cipro; 15mg/kg, 2 
doses over 24 h). Untreated mice served as reference controls. Heatmaps show the effect of each 
of the treatments on animals from Charles Rivers Labs (CRL) and Envigo Labs (Envigo). Each 
row represents a species-level bacterial taxon, while each column represents a mouse sampled 24 
hours after the termination of the indicated treatment. Colored boxes next to the taxon names 
indicate species whose relative abundance was significantly changed by Cipro treatment 
(p<0.05;Wilcoxon Signed Rank test with FDR correction). Individual comparisons between 
untreated and other treatment types did not disclose changes that were statistically significant by 
Wilcoxon Signed Rank test with FDR correction. (b) Corresponding fecal samples collected 24 h 
after treatments (as shown in Extended Data Figure 8a) were homogenized, diluted serially, and 
plated on MacConkey medium. The abundance of bacteria capable of growing on the selective 
medium was similar between fecal samples taken from untreated mice and those collected 24 
hours after treatment with cyclodextrin and M4284. No colonies were detected from fecal 
samples collected 24 hours after ciprofloxacin treatment. n=5 mice, 1 replicate. Bars= median 
value, **p<0.001 (Mann Whitney U test). (c) Comparison of the representation of bacterial taxa 
in the fecal microbiota of untreated mice obtained from different vendors or representing 
different genetic backgrounds.  Each row in the heatmap represents a species-level taxon, while 
each column represents a mouse of the indicated genetic background from the indicated vendor. 
Colored boxes indicate species whose relative abundances were significantly different (p<0.05) 
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between all three groups of animals (Kruskal-Wallis test with FDR correction). Rows of each 
heatmap were hierarchically clustered according to pair-wise distances using Pearson correlation. 
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Figure 15. Bacterial 16S rRNA-based analysis showing that the fecal microbiota of 
C3H/HeN mice pretreated with streptomycin and colonized with UTI89 is minimally 
altered by M4284 treatment. (a) C3H/HeN mice from Envigo were pretreated with 
streptomycin and 24 h later colonized with UTI89 by oral gavage. Three days after inoculation, 
mice were treated with 3 doses of M4284 (100mg/kg, 3 doses over 24 h) or vehicle alone (10% 
cyclodextrin (Cyclo), 3 doses over 24 h). Fecal samples were collected 24 h after the last dose of 
M4284 or vehicle. (b) Heatmap showing the effect of each treatment type. Each row represents a 
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bacterial species-level taxon, while each column represents a mouse 24 h after the indicated 
treatment. Rows of the heatmap were hierarchically clustered according to pair-wise distances 
using Pearson correlation. No treatments produced changes that were statistically significant, as 
judged by Wilcoxon Signed Rank test with FDR correction. 
 
 
Figure 16. The percent reduction in strains by M4284 treatment is similar in mice 
colonized with genetically distinct human isolates and in multiple strains of mice colonized 
by UTI89. (a) The percent reduction in the indicated UPEC strains from M4284-treated versus 
untreated control C3H/HeN mice from Envigo (based on data presented in Fig. 4c-f). (b) These 
values were also determined for C3H/HeN mice from Charles Rivers Labs (CRL) and C57BL/6 
mice from Envigo (based on data shown in Fig. 4g,h). P values based on Kruskal-Wallis test. 
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Chapter 4: Conclusions and Future 
Directions 
Significance 
 The steady increase in the number of clinical infections caused by single and multi-drug 
resistant bacterial pathogens worldwide highlights the antibiotic crisis we currently face. A 
recent review on antimicrobial resistance headed by the British government has indicated that 
unless we intervene now, superbugs could kill more people than cancer by 2050.  
 One manifestation of this crisis are urinary tract infections (UTI) caused by UPEC. Over 
a hundred million people are affected by UTIs each year. The global prevalence of UPEC strains 
resistant to so-called ‘last-line antibiotics’ like fluoroquinolones and now carbepenems is 
increasing at an alarming rate and may foreshadow the end of the road for antibiotics in the 
treatment of some patients with UTIs.  
 The mechanisms by which UPEC cause acute and recurrent UTIs have been studied 
extensively; this includes analyses of the roles of chaperone-usher pathway (CUP) pili in 
colonization of the bladder and kidneys. While UPEC cause infection in the urinary tract, the gut 
is considered to serve as a primary reservoir from which UPEC strains can emerge to colonize 
the vagina and peri-urethral area, and subsequently the bladder. However, prior to my thesis 
work, little was known regarding the mechanism(s) by which UPEC is able to establish itself in 
the gut.  
 Ultimately, my research has provided significant advances in our knowledge of UPEC 
pathogenesis. My work revealed novel E. coli virulence factors (type 1 and F17-like pili) that 
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promote intestinal colonization by UPEC. Identification of a role for F17-like pili in intestinal 
colonization provides new insights into a previously uncharacterized CUP pilus type. 
Identification of a role for type 1 pili in intestinal colonization reveals a new, unexpected 
function for a pilus that is essential for infection in the bladder. 
  I also present a new antibiotic-sparing approach for precision targeting of UPEC in its 
intestinal reservoir. If taken to clinical practice, such a treatment would reduce the exposure of 
the gut bacterial community to antibiotics. Further, administration of high-affinity mannosides 
offers an opportunity to use these compounds as ‘probes’ to identify potential interactions 
between other members of the human gut microbial community and mannose-containing glycans 
present in the body. Overall, my thesis work provides a powerful example of how anti-microbial 
measures can selectively deplete a bacterial pathogen, within the context of the complex gut 
microbial community, during acute infection or from its asymptomatic reservoir.  
 
Future Directions 
Where is the UclD ligand-binding site?  
 Based on the structural homology between UclD and F17G, I identified a putative ligand-
binding site on the crystal structure of UclD. Further, due to their location within the putative 
pocket, I identified six residues that I hypothesize to mediate ligand binding. Moving forward, it 
will be important to verify this putative binding site. One way to verify that this is the correct site 
would be a mutagenesis study. By mutating each of the hypothesized ‘key’ residues and 
assessing their ability to bind to the upper region of the colonic crypts in mouse sections, I would 
be able to confirm the location of the binding site. If none of the hypothesized residues result in 
the loss of crypt binding, then I would turn to in silico modeling to predict other regions of the 
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protein that could contain a ligand-binding site and perform a similar mutagenesis study. 
Identifying residues that are critical to ligand binding by UclD is necessary for the creation of 
small-molecule ligand antagonists that could be used to target the function of F17-like pili in the 
gut. 
What is the ligand bound by UclD?  
 The other essential piece of information required to develop small-molecule ligand 
antagonists that target UclD is the identity of the ligand bound by the adhesin. No binding of 
UclD is observed to any ligands present on the Center for Functional Glycomics glycan array nor 
have we identified a ligand using differential scanning fluorimetry (DSF). However, my work 
suggests that the ligand bound by UclD is contained within an O-glycan. Excitingly, 
correspondence with Dr. Richard Cummings, the direction of the Center for Functional 
Glycomics, has indicated that the center is producing an array containing only structural 
variations of O-glycans. This ‘O-glycan’ array will provide a platform tailored toward finding a 
potential ligand(s) for UclD. In tandem with the “O-glycan” array, I would also perform in silico 
screens to identify ligands that bind virtually within the UclD binding pocket. This type of 
analysis would allow us to screen a large number of potential ligands, including those contained 
within O-glycans. Any ligands identified via in silico screens or through the ‘O-glycan’ array 
would be verified using differential scanning fluorimetry (DSF) and/or Bio-layer Interferometry 
(BLI).  
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Does oral mannoside treatment effect the commensal E. coli population? 
 In collaboration with Dr. Jeffrey Gordon and Dr. Andrew Kau, I was able to show that 
oral mannoside exposure has minimal effects on the overall structure of the mouse fecal 
microbiota. Interestingly, while most Enterobacteriaceae carry the fim operon1-3, mannoside 
treatment does not significantly affect the abundance of intestinal Enterobacteriaceae, suggesting 
that these bacteria may not be expressing type 1 pili during mannoside exposure or that they 
reside within inaccessible intestinal habitats. However, further examination of the effects of 
mannoside treatment on gut colonization by different species/strains of Enterobacteriaceae is 
needed to more fully interpret the significance of these findings.  
 Because E. coli makes up a very small portion of the overall microbiota population, 16S 
rRNA sequencing is not the most sensitive way to explicitly determine the effect of oral 
mannoside treatment on this population. A better way to directly assess the effects of oral 
mannoside treatment on the commensal E. coli population would be to examine gnotobiotic mice 
harboring defined microbiota communities. After inoculating gnotobiotic mice with defined 
microbiota communities (made up of ~10-15 members that represent bacteria associated with the 
microbiota of healthy individuals, including different species/strains of Enterobacteriaceae), I 
could treat the mice with mannosides and then track the colonization levels of the organisms in 
the defined community, including levels of the type 1 pilus-encoding Enterobacteriaceae. This 
type of experiment would allow me to directly examine if and/or how mannoside treatment alters 
the colonization levels of Enterobacteriaceae. Further, performing this experiment in gnotobiotic 
mice that are also colonized intestinally by UPEC prior to oral mannoside treatment would allow 
me to determine if mannoside treatment selectively extirpates UPEC while leaving the rest of the 
microbiota, including the commensal E. coli strains, untouched. 
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 One of my hypotheses for why mannoside treatment may not alter type-1 encoding 
commensal Enterobacteriaceae is that, unlike UPEC strains, these bacteria do not express type 1 
pili in the gut. Examining which CUP pilus types are expressed by commensal E. coli in naïve 
mice (that have not been exposed to UPEC or streptomycin, or in mice that have been treated 
with streptomycin but not inoculated with UPEC) would begin to test the validity of this 
hypothesis. Performing RT-PCR on RNA extracted from feces, cecal content, or colon content 
from these mice would be one way to determine which CUP pilus types are being expressed by 
commensal Enterobacteriaceae. Additionally, I could inoculate gnotobiotic mice with E. coli 
strains that express genetically encoded fluorescent proteins. After treating these mice with a 
fluorescently conjugated mannoside, I could perform immunohistochemistry on colon sections 
from these mice. This would allow me to simultaneously investigate the expression of type-1 pili 
and delineate the localization of E. coli in this mouse model. 
What are the mannoside structures that work best to target UPEC in the gut? 
 Not all available mannoside compounds have the same efficacy in the gut. Out of six 
compounds I tested, two compounds reduced UTI89 titers in the intestines, two had no effect, 
and two appear to slightly increase UTI89 colonization (Figure 17). Differences in the efficacy 
of these compounds could be due to a number of variables, including: bioavailability in the gut 
and/or the ability to withstand cleavage by intestinal enzymes. Testing a panel of structurally 
distinct mannoside compounds with varied functional groups in our mouse model of UPEC 
intestinal colonization would provide some insight into which functional groups and core 
structures are the most effective in vivo. Further, analyzing the bioavailability (in the serum, 
feces, and urine) of compounds that both successfully and unsuccessfully target intestinal UPEC 
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in mice would provide insight into how changing the chemical structures of the compounds alters 
the ability of the compound to reach the desired host site.  
 
 
Figure 17. Not all mannoside compounds reduce the intestinal UPEC population. C3H/HeN 
female mice were pretreated with streptomycin and colonized with UTI89. Starting at 3 days 
post UTI89 colonization, mice were given three doses of a mannoside compound (100mg/kg) or 
10% cyclodextrin (ctrl) (PO). UTI89 levels in the feces and intestinal tissue were assessed 8 
hours after the last dose was given.  
Does UPEC bind in the colonic crypts in vivo? 
 Using immunofluorescence (IF) studies, our collaborators in Han Remaut’s lab found that 
the purified lectin domains of FimH and UclD bind to distinct areas within mouse colonic crypts. 
This led us to speculate that in vivo, FimH may promote binding to the upper region of the crypts 
and surface epithelial cuffs while UclD binds a ligand in the lower crypts. However, several 
limitations of this IF study are: 1) binding was assessed with purified protein, rather than with 
whole bacteria, and 2) we observed binding to colonic sections that were mounted on microscope 
slides, rather than in vivo.  
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 To address the first point, we chose to examine binding with purified protein, rather than 
whole bacteria because using bacteria introduces variables that are difficult to control. For 
example, even when we grow UPEC strains under in vitro conditions shown to induce 
expression of type 1 pili, we still observe expression of other pili (S and P types), by RNA and 
functional analyses3,4. Furthermore, when we genetically engineer the promoter of fimS to remain 
in the Phase ON orientation, thus “locking ON” type 1 pilus expression, there is still some 
expression of other CUP pilus types4. Thus, obtaining a pure population of UPEC expressing 
exclusively one pilus type is not straightforward and complicated by co-expression of other pilus 
types. Therefore, we feel that using purified protein is currently the best way to explicitly 
characterize the role of a specific pilus type in tissue binding.  
 Addressing the second limitation of our study, colonic sections were used because 
imaging of bacterial binding in vivo is currently limited to techniques like in vivo 
bioluminescence imaging, which provides a general idea of the organ where binding is occurring 
but cannot provide the cellular detail we gain by imaging tissue sections. However, a major 
question derived from our findings that purified protein binds within the colonic crypts is: does 
UPEC bind within the crypts in mice and/or humans or is it an artifact of sectioning tissue?  
 In order to colonize the colonic epithelium, a bacterium first must overcome the 
formidable barriers established by the host. The first level of that barrier is the secretion of 
antimicrobial peptides (AMPs) by colonic enterocytes. AMPs like β-defensins and cathelicidins 
target a wide range of microbes, including gram positive and negative bacteria, fungi, and 
viruses, and work to dramatically reduce the number of microbes that can directly interact with 
the host surface5. The second major host barrier is the presence of colonic mucus. The mucus 
layer is made up of two layers, an outer and inner layer. The outer mucus layer is thicker than the 
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inner layer (~100 µm in mice) and is commonly colonized by bacteria6. The outer layer of mucus 
is constantly turning over and shedding older mucus into the lumen of the gut, which are then 
expelled in the feces. The shedding of the outer mucus layer makes it more difficult for bacteria 
to transit through this layer to colonize the inner layer or epithelium. The inner mucus layer is 
attached to the colonic epithelium and ranges in thickness from 50 µm in mice to over 100 µm in 
humans6. In the past, it was thought that the inner mucus layer is largely devoid of bacterial 
colonization. However, recent imaging studies using a fixative that preserves the mucus layer 
(Carnoy’s Fixative) identified bacteria in a “significant fraction” of colonic crypts from healthy 
mice, indicating that this inner membrane is not sterile7. Interestingly, studies profiling crypt-
associated bacterial communities using laser microdissection and sequencing found that this 
habitat is often enriched for Proteobacteria capable of aerobic metabolism, like E. coli8.  
 However, for UPEC to colonize the crypts they must also be able to access and bind a 
ligand. Unfortunately, not knowing the ligand for the UclD adhesin limits our ability to 
determine if a corresponding ligand is present in the lower crypts. Nonetheless, we can explore 
the presence of a mannose containing ligand in this habitat.  
 Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) are a group of 
immunoglobulin-related glycoproteins that are highly mannosylated. Several CEACAM family 
members, including CEACAM1, CEACAM6, and CEACAM7, are associated with the normal 
colorectal mucosa9. Excitingly, one of these receptors, CEACAM7, has been shown to localize 
to the apical surface of highly differentiated epithelial cells in the colorectal mucosa, like those 
found in the upper crypts and in epithelial surface cuffs9. The presence of a highly mannosylated 
receptor in the same region were we observe FimH binding in our mouse colon sections, 
suggests that CEACAM7 might act as a ligand for FimH in vivo. Another CEACAM that has 
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been well studied is CEACAM6. While CEACAM6 is expressed at low levels within crypts of 
healthy individuals, CEACAM6 levels are elevated in the crypts of patients with colorectal 
cancer9,10. One study, using a chronic infection model of CEACAM6 expressing mice, showed 
that a B2 E. coli strain isolated from a patient with colon cancer persists to high levels in the gut, 
induces colon inflammation, epithelial damages and cell proliferation11. This study did not test 
whether colonization, in these mice, was mediated by type 1 pili, however, my findings suggest 
that this enhanced intestinal colonization could be mediated by the interaction between type 1 
pili and CEACAM6. The ability of FimH to bind to the host intestinal surface in vivo is further 
supported by studies finding that patients with the IBD syndrome Crohn’s disease (CD) express 
abnormally high levels of CEACAM6 on their ileal epithelium12-15, which is bound by type 1 pili 
expressing adherent-invasive E. coli (AIEC). 
 Altogether, these data suggest that there is a mannose containing ligand in the upper 
colonic crypts that could be bound by FimH. However, the thick mucus layer, microbiota, and 
plethora of AMPs could make accessing the crypts challenging, particularly in a healthy host.  
 An interesting way to test the ability of FimH or UclD to bind within the crypts in a more 
physiological setting would be to use intestinal spheroid systems. Spheroids take advantage of 
proliferative stem/progenitor cells which can be rapidly expanded using conditioned media that 
contains signaling proteins that promote cellular growth (Wnt3a, R-spondin and Noggin)16. Upon 
differentiation, these cells maintain structural and cellular characteristics of intestinal cells. 
When grown on a transwell membrane, spheroids form crypts and functional, polarized 
monolayers covered by a secreted mucus16. While spheroids do not completely replicate the 
intestinal environment (they lack a microbiota and immune system), they would allow us to 
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determine if the adhesins bind to the same locations in human cells and in the presence of a 
mucus membrane. 
Does the type of intestinal inflammation effect which CUP pili are used for gut 
colonization? 
 The majority of characterized CUP adhesins bind glycan moieties; therefore, any changes 
in the intestinal glycan landscape, including altered expression of glycosylated proteins, could 
expose ligands for CUP pilus types. Interestingly, previous work has found that the presence of 
distinct CUP pilus ligands differs between body sites/habitats and, in some cases, is influenced 
by inflammation. For example, Fml pili promote colonization of the bladder during chronic 
cystitis, a state of severe, chronic bladder inflammation17. The Fml pilus adhesin, FmlH, binds to 
Gal (β1-3) GalNAc, which is only expressed on the surface of the bladder epithelium during 
periods of bladder inflammation and remodeling. Accordingly, studies have found that intestinal 
disorders and dysbioses have divergent effects on the gut environment, altering the composition 
of the microbiota and stimulating distinct immune responses. Interestingly, the inflammatory 
state influences the intestinal glycan landscape in the gut of patients with CD. High levels of 
intestinal inflammation and/or bacterial dysbiosis cause patients with CD to express abnormally 
high levels of CEACAM6 on their ileal epithelium12-15. And as stated before, CEACAM6 is 
bound by type 1 pili expressing adherent-invasive E. coli (AIEC). 
 To determine how distinct types of intestinal inflammation alter the role of CUP pili in 
UPEC intestinal colonization, I would examine the ability of individual CUP pilus mutant strains 
to compete with the isogenic wildtype strain (UTI89) in IL-10 deficient mice, which are prone to 
spontaneous colitis18, or in mice treated with dextran sulfate sodium (DSS). DSS is a chemical 
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inducer of colitis and is an accepted mouse model of IBD19,20. DSS, which results in the 
recruitment of mainly neutrophils to the gut, has a different inflammatory response than 
streptomycin, which results in recruitment of both neutrophils and inflammatory monocytes20-23. 
Interestingly, I found that treating C3H/HeN mice with DSS, ad libitum, greatly enhances UPEC 
intestinal fitness (Figure 18). In DSS treated mice, UTI89 colonization of the gut occurs for a 
more protracted period of time than is observed in streptomycin treated mice. The distinct impact 
of these two treatments on the intestinal environment may effect the intestinal glycan landscape 
in a way that effects which CUP pilus types are used by UPEC to colonize the intestine.  
 
 
Figure. 18. Stimulating acute colitis in mice increases UTI89 intestinal colonization. 
Streptomycin treated mice were colonized with UTI89. Starting at 7 days post infection (dpi) 
mice were provided drinking water supplemented with (red) or without (black) 3% DSS. 
Longitudinal fecal (A) and tissue (B)  (at 28 dpi) show that DSS treatment enhances UPEC 
intestinal colonization. Mann-Whitney U test, **p<0.01, ***p<0.001, ***p<0.0001. 
Which CUP pili promote intestinal colonization by other uropathogens and 
enteropathogens? 
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 Like UPEC, other uropathogens (such as Proteus, Enterobacter, and Klebsiella species) 
reside in the gut and are able to cause UTI after being shed in the feces and entering the bladder. 
However, the bacterial factors that promote intestinal colonization by these uropathogens are 
understudied. Each of these bacterial species encode a range of CUP pilus types, some of which 
have been shown to promote UTI1. For example, in a mouse model of UTI caused by Klebsiella 
pneumoniae, type 1-mediated binding to mannose is indispensible for invasion into urothelial 
cells and the formation of IBCs24. Yet, a role for CUP pilus types utilizes by these uropathogens 
in the gut has not been explored. This is an interesting question to pursue since many of these 
organisms contain CUP pili that are distinct from those carried by UTI89 (for example, 
Klebsiella species carry type 3 pili, which are absent in UPEC) and thus may uncover roles for 
other uncharacterized pilus types. Further, identifying bacterial factors, like CUP pilus types, that 
promote colonization of these non-UPEC uropathogens in the gut is necessary to gain insight 
into how these organisms cause disease in the host and may provide targets for anti-adhesive 
drugs.  
 Following the same experimental plan outlined in Chapter 2, I would identify CUP pilus 
types that promote intestinal colonization by non-UPEC uropathogens (i.e. creating individual 
CUP pilus deletion mutants in each background strain and test their ability to compete with an 
isogenic wildtype strain in the streptomycin mouse model). A benefit of this experimental plan is 
that it can also be adapted to identify CUP pilus types that promote intestinal colonization by 
enteropathogens, like AIEC.  
 Moreover, identification of intestinally expressed CUP pilus types and their 
corresponding ligands for non-UPEC uropathogens or enteropathogens could allow for the 
development of ligand antagonists, like mannosides.   
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 An exciting finding would be identifying a role for type 1 pili in intestinal colonization 
by any of the non-UPEC strains, as this would allow us to test the efficacy of mannosides to 
target these organisms in the gut.  
 Perhaps one of the most promising candidates would be Klebsiella species, which carry 
type 1 pili and, like UPEC, have been shown to use these pili during UTI24. If type 1 pili promote 
Klebsiella intestinal colonization then oral mannoside treatment might be effective at targeting 
and reducing the Klebsiella population in both the gut and bladder.  
 Of note, however, sequence variation in the FimH adhesin between UPEC strains and K. 
pneumoniae results in differences in the function of the type 1 pilus in the bladder. In K. 
pneumonia, for example, FimH-dependent biofilm formation is inhibited by heptyl mannose, but 
not methyl mannose, suggesting that mannose binding to the K. pneumoniae FimH may involve 
contacting residues outside of the mannose binding pocket and thus may be more complex than 
what occurs in UPEC 24. Changes in the mannose-FimH interaction in Klebsiella might alter the 
ability of mannosides to effectively target this organism in the gut. In this case, examining the 
ability of mannoside to target and reduce type-1 expressing Klebsiella from binding to guinea pig 
red blood cells in vitro (via hemagglutination assays), would be a good start to determine if 
mannoside could block FimH activity of Klebsiella species. 
 Another promising candidate might be AIEC, which use type 1 pili and FimH to bind to 
ligands present in the gut. As discussed earlier, AIEC use type 1 pili to bind to CEACAM6 on 
the ileal surface during period of intestinal inflammation. To determine if oral mannoside 
treatment could target and reduce the AIEC population and potentially reduce intestinal 
inflammation in CD patients, I would intestinally colonize mice (either using my streptomycin 
model or using IL-10 KO mice) with AIEC and then treat the mice with mannosides. Assessing 
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the overall number of AIEC present in treated versus control mice would allow me to examine if 
mannosides target AIEC in the gut.  
 It would also be interesting to determine if mannoside treatment has any effect on the 
level or type of intestinal inflammation or the overall structure of the microbiota in mice with 
IBD-like syndromes (IL-10 deficient mice or DSS treated mice). Microbial dysbiosis is 
associated with the onset and/or severity of IBD in patients. Therefore, if mannoside treatment is 
able to reduce the AIEC population in the gut, it might free up niche space or nutrients for 
competing organisms and thus alter the microbiota structure in a way that could change the 
inflammatory state. Performing cytokine analyses on serum and fecal, cecal, or colon contents 
from mice treated with mannosides would provide insight into any effects mannoside treatment 
might have on the inflammatory state of mouse models of IBD. Further, 16S rRNA profiling of 
the fecal microbiota of these mice would also allow me to determine how oral mannoside 
treatment alters the structure of the gut microbiota. 
Will oral mannoside treatment work to reduce UPEC in the gut and bladder of humans? 
 In the end, evaluation of the efficacy and safety of mannosides in the treatment and 
prevention of UTI in humans will require clinical trials. I envision that such a trial would enroll 
young females (college age) who have a history of chronic/recurrent UTI (3 or more UTIs a 
year). Upon experiencing a UTI, these women would be enrolled into the study, an enrollment 
urine and fecal sample would be collected, and they would receive treatment with an appropriate 
antibiotic. Following this, half of the women would receive long-term daily treatment with an 
oral mannoside and half the women would be treated with a placebo control. Longitudinal fecal 
collection would take place, allowing us to examine the effect of mannoside on the UPEC 
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population in the gut and on the overall structure of the microbiota over time. Rates of recurrent 
UTI would also be determined in control vs. mannoside treated individuals. 
 This study design, which mimics a study that has been done to examine the affects of 
drinking cranberry juice on UTI frequency25, would evaluate the efficacy of mannoside treatment 
on reducing the rate of recurrent UTIs and its effect on the bacteria present in the gut microbiota.   
How will UPEC develop resistance to mannosides? 
 The ability of bacteria to develop and spread resistance to therapeutics and antibiotics is 
causing a major health care crisis. Creating treatments, like mannosides that can selectively 
target specific bacteria while leaving the remainder of the microbiota unharmed could help to 
slow the development and spread of resistance. However, what are the chances that UPEC will 
develop resistance to mannosides, leaving these compounds ineffective? 
 Bacteria spread resistance through vertical transmission, where mutations that promote 
resistance are passed through a population by replication, or through horizontal transmission, 
where resistance genes can be swapped from one microbe to another. Regardless of how a 
microbe acquires them, resistance genes can function through a number of distinct mechanisms, 
including: i) making the cell wall impermeable to the drug, ii) altering the protein bound by the 
drug, iii) producing an enzyme(s) that cleaves the drug into an inactive form or degrade it, or iv) 
removing the drug from inside the cell via efflux pumps or transporters26.  Because mannosides 
target a virulence factor expressed on the extracellular surface of UPEC, resistance mechanisms 
that prevent the drug from entering or remaining in the bacterial cell are not of concern. While 
UPEC might develop or recycle an enzyme to cleave mannosides, this enzyme would need to 
differentiate mannosides from mannose or risk cleaving the endogenous ligand for the type 1 
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pilus. Altering the protein bound by the mannosides is also possible, however, there are several 
reasons why this method of resistance is also not ideal for UPEC.  
 To develop resistance in this manner, UPEC would need to evolve a FimH protein that is 
resistant to mannoside binding but retains its ability to bind mannose. However, type 1 pili and 
the FimH adhesin are highly conserved throughout enterobacteriaceae. In fact, the residues that 
make up the FimH binding pocket are invariant among all sequenced UPEC strains. Further, 
unlike antibiotics that kill or stall bacterial growth, mannosides prevent the function of a non-
essential colonization factor, creating less selective pressure to develop resistance to the drug.  
 Despite all this, the development of resistance to mannosides is certainly possible. It may 
be possible to predict the type of genetic mutations that would provide resistance. Random 
mutagenesis of the FimH protein followed by screening these mutagenized adhesins for variants 
that retain D-mannose binding but are resistant to mannoside might provide a resistant variant 
What other bacterial genes are important for UPEC intestinal colonization? 
 I anticipate that bacterial genes other than CUP pili play a role in UPEC intestinal 
colonization. To determine what other genes are important for gut colonization, I would first 
want to assess the feasibility of performing a broad unbiased mutagenesis screen of UPEC in the 
gut. First, I would test for an intestinal bottleneck using an isogenic set of UTI89 derivatives, 
each carrying a unique genetic barcode tag27. A gut colonization bottleneck would preclude my 
ability to assess the fitness of large collections of different mutants simultaneously in the gut 
model, and thus make the screening of large random mutant library impractical. If there is no 
severe gut colonization bottleneck, I would use a transposon mutant library that is already made 
in UTI89 and screen for mutations that are defective in gut colonization using TnSeq28.  
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Impact and Closing Remarks  
 In this work, I identify novel E. coli virulence factors (type 1 and F17-like pili) that 
promote intestinal colonization. I also present a new antibiotic-sparing approach for precision 
targeting of UPEC in its intestinal reservoir. If taken to clinical practice, such a treatment would 
reduce the exposure of the gut bacterial community to antibiotics. Further, administration of 
high-affinity mannosides offers an opportunity to use these compounds as ‘probes’ to identify 
potential interactions between other members of the human gut microbial community and 
mannose-containing glycans present in this body habitat that affect their fitness.  
 Identification of the F17-like pilus in intestinal colonization provides new insights into a 
previously uncharacterized CUP pilus type. This data suggest, unexpectedly, that extra-intestinal 
pathogenic E. coli, like UPEC, acquired an F17-family CUP from intestinal pathogens, and 
evolved it into a unique virulence factor that promotes the establishment and/or maintenance of 
an asymptomatic UPEC intestinal reservoir. Identification of genes involved in UPEC 
colonization of the gut provide new avenues for therapeutic development and may also provide a 
method to stratify UTI patients for epidemiologic studies of recurrent disease risk as well as for 
proof of concept clinical studies of the efficacy of CUP-directed treatment regimens: end point 
markers for such studies could include reduction/elimination of the intestinal reservoir, treatment 
of acute UTI and reduction in rUTI.  
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Supplementary Tables 
Supplementary Table 1: The phylogenetic relationships between F17 homologs as 
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determined by comparing relatedness of bacterial usher gene sequences. 
ENA 
Sequence 
ID Name of Sequence 
Percent 
Identity 
to UTI89 
uclC 
ABE10308 Escherichia coli UTI89 putative F17-like fimbrial usher 100 
EFJ62248 Escherichia coli MS 200-1 fimbrial usher protein 100 
EFU54800 Escherichia coli MS 153-1 fimbrial usher protein 100 
EGB83651 Escherichia coli MS 60-1 fimbrial usher protein 100 
ESE31717 Escherichia coli A35218R fimbrial usher protein 100 
ADN73675 Escherichia coli UM146 putative F17-like fimbrial usher 100 
ALD32943 Escherichia coli F17 fimbrial usher 100 
EDV68536 Escherichia coli F11 fimbrial usher protein 100 
ELC94190 Escherichia coli KTE191 F17-like fimbrial usher 100 
ELD03594 Escherichia coli KTE201 F17-like fimbrial usher 100 
ELD16276 Escherichia coli KTE206 F17-like fimbrial usher 100 
ELE16801 Escherichia coli KTE55 F17-like fimbrial usher 100 
ELF44072 Escherichia coli KTE8 F17-like fimbrial usher 100 
ELH71006 Escherichia coli KTE215 F17-like fimbrial usher 100 
ELI17337 Escherichia coli KTE106 F17-like fimbrial usher 100 
ELI42231 Escherichia coli KTE124 F17-like fimbrial usher 100 
ELI66860 Escherichia coli KTE131 F17-like fimbrial usher 100 
ELI88553 Escherichia coli KTE145 F17-like fimbrial usher 100 
EQN12131 Escherichia coli HVH 4 (4-7276109) F17-like fimbrial usher 100 
EQO02162 Escherichia coli HVH 28 (4-0907367) F17-like fimbrial usher 100 
EQP01733 Escherichia coli HVH 56 (4-2153033) F17-like fimbrial usher 100 
EQP59624 Escherichia coli HVH 77 (4-2605759) F17-like fimbrial usher 100 
EQQ43504 Escherichia coli HVH 100 (4-2850729) F17-like fimbrial usher 100 
EQQ70585 Escherichia coli HVH 111 (4-7039018) F17-like fimbrial usher 100 
EQQ80267 Escherichia coli HVH 112 (4-5987253) F17-like fimbrial usher 100 
EQS09284 Escherichia coli HVH 143 (4-5674999) F17-like fimbrial usher 100 
EQS64201 Escherichia coli HVH 161 (4-3119890) F17-like fimbrial usher 100 
EQS94171 Escherichia coli HVH 171 (4-3191958) F17-like fimbrial usher 100 
EQV28377 Escherichia coli KOEGE 30 (63a) F17-like fimbrial usher 100 
EQV75237 Escherichia coli KOEGE 70 (185a) F17-like fimbrial usher 100 
EQX61640 Escherichia coli UMEA 3185-1 F17-like fimbrial usher 100 
EQX71663 Escherichia coli UMEA 3193-1 F17-like fimbrial usher 100 
EQY26881 Escherichia coli UMEA 3220-1 F17-like fimbrial usher 100 
EQY49990 Escherichia coli UMEA 3244-1 F17-like fimbrial usher 100 
EQZ33281 Escherichia coli UMEA 3617-1 F17-like fimbrial usher 100 
ERA15291 Escherichia coli UMEA 3834-1 F17-like fimbrial usher 100 
ERA29104 Escherichia coli UMEA 3955-1 F17-like fimbrial usher 100 
ERA85411 Escherichia coli HVH 228 (4-7787030) F17-like fimbrial usher 100 
ERB29121 Escherichia coli UMEA 3298-1 F17-like fimbrial usher 100 
ESK12150 Escherichia coli UMEA 3290-1 F17-like fimbrial usher 100 
ESK22344 Escherichia coli UMEA 3426-1 F17-like fimbrial usher 100 
ESK23671 Escherichia coli UMEA 3693-1 F17-like fimbrial usher 100 
ETF18627 Escherichia coli HVH 23 (4-6066488) F17-like fimbrial usher 100 
EZQ53413 Escherichia coli BIDMC 83 F17-like fimbrial usher 100 
KDG55831 Escherichia coli CHS 69 hypothetical protein 100 
KDN08559 Escherichia coli Outer membrane usher protein htrE precursor 100 
KDO88538 Escherichia coli F17 fimbrial usher 100 
KDT41029 Escherichia coli 3-105-05_S4_C2 type VII secretion system (T7SS), usher family protein 100 
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KDY41355 Escherichia coli 2-427-07_S4_C2 type VII secretion system (T7SS), usher family protein 100 
KEJ39633 Escherichia coli 2-460-02_S1_C3 type VII secretion system (T7SS), usher family protein 100 
KEO42424 Escherichia coli 2-460-02_S1_C2 type VII secretion system (T7SS), usher family protein 100 
KIE65152 Escherichia coli F17 fimbrial usher 100 
KLX09881 Escherichia coli F17-like fimbrial usher 100 
KLX89280 Escherichia coli F17-like fimbrial usher 100 
KLX98072 Escherichia coli F17-like fimbrial usher 100 
KLY02293 Escherichia coli F17-like fimbrial usher 100 
KNY00060 Escherichia coli F17 fimbrial usher 100 
KSX67622 Escherichia coli F17 fimbrial usher 100 
KSX77117 Escherichia coli F17 fimbrial usher 100 
KSY42022 Escherichia coli F17 fimbrial usher 100 
KTK66169 Escherichia coli F17 fimbrial usher 100 
KUR86703 Escherichia coli F17 fimbrial usher 100 
KUS25287 Escherichia coli F17 fimbrial usher 100 
KUS30331 Escherichia coli F17 fimbrial usher 100 
KUS39441 Escherichia coli F17 fimbrial usher 100 
KUS56802 Escherichia coli F17 fimbrial usher 100 
KUS66696 Escherichia coli F17 fimbrial usher 100 
KUS97674 Escherichia coli F17 fimbrial usher 100 
KUS99347 Escherichia coli F17 fimbrial usher 100 
KUV71654 Escherichia coli F17 fimbrial usher 100 
KUW51062 Escherichia coli F17 fimbrial usher 100 
KUW91068 Escherichia coli F17 fimbrial usher 100 
KUW97800 Escherichia coli F17 fimbrial usher 100 
KUX04485 Escherichia coli F17 fimbrial usher 100 
KUX29835 Escherichia coli F17 fimbrial usher 100 
KXL01352 Escherichia coli F17 fimbrial usher 100 
KZH53165 Escherichia coli F17 fimbrial usher 100 
KZH65083 Escherichia coli F17 fimbrial usher 100 
KZJ04397 Escherichia coli F17 fimbrial usher 100 
KZP40296 Escherichia coli F17 fimbrial usher 100 
AJM76553 Escherichia coli RS218 F17 fimbrial usher 100 
KIE78191 Escherichia coli RS218 F17 fimbrial usher 100 
ELC78257 Escherichia coli KTE189 F17-like fimbrial usher 100 
ELI07650 Escherichia coli KTE104 F17-like fimbrial usher 100 
EQW59606 Escherichia coli UMEA 3113-1 F17-like fimbrial usher 100 
ERA28987 Escherichia coli UMEA 4075-1 F17-like fimbrial usher 100 
EQV60654 Escherichia coli KOEGE 58 (171a) F17-like fimbrial usher 99.9 
EOV01926 Escherichia coli KTE195 F17-like fimbrial usher 100 
EQP64368 Escherichia coli HVH 78 (4-2735946) F17-like fimbrial usher 100 
EQV60901 Escherichia coli KOEGE 58 (171a) F17-like fimbrial usher 99.9 
ELL39501 Escherichia coli J96 putative F17-like fimbrial usher 99.7 
KLX25294 Escherichia coli F17-like fimbrial usher 99.7 
ELD47794 Escherichia coli KTE224 F17-like fimbrial usher 99.7 
ELE94443 Escherichia coli KTE87 F17-like fimbrial usher 99.7 
ELF33437 Escherichia coli KTE169 F17-like fimbrial usher 99.7 
ELF79243 Escherichia coli KTE43 F17-like fimbrial usher 99.7 
ELH90555 Escherichia coli KTE218 F17-like fimbrial usher 99.7 
ELJ02444 Escherichia coli KTE153 F17-like fimbrial usher 99.7 
ELJ33477 Escherichia coli KTE168 F17-like fimbrial usher 99.7 
EQN27402 Escherichia coli HVH 7 (4-7315031) F17-like fimbrial usher 99.7 
EQN57805 Escherichia coli HVH 20 (4-5865042) F17-like fimbrial usher 99.7 
EQO39143 Escherichia coli HVH 38 (4-2774682) F17-like fimbrial usher 99.7 
EQO97005 Escherichia coli HVH 55 (4-2646161) F17-like fimbrial usher 99.7 
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EQP16163 Escherichia coli HVH 61 (4-2736020) F17-like fimbrial usher 99.7 
EQP98545 Escherichia coli HVH 89 (4-5885604) F17-like fimbrial usher 99.7 
EQU05851 Escherichia coli HVH 197 (4-4466217) F17-like fimbrial usher 99.7 
EQU53211 Escherichia coli HVH 207 (4-3113221) F17-like fimbrial usher 99.7 
EQV19738 Escherichia coli HVH 225 (4-1273116) F17-like fimbrial usher 99.7 
EQW65711 Escherichia coli UMEA 3088-1 F17-like fimbrial usher 99.7 
EQX13871 Escherichia coli UMEA 3160-1 F17-like fimbrial usher 99.7 
ERA80937 Escherichia coli HVH 160 (4-5695937) F17-like fimbrial usher 99.7 
ERF50184 Escherichia coli UMEA 3652-1 F17-like fimbrial usher 99.7 
KDY17150 Escherichia coli 2-316-03_S4_C3 type VII secretion system (T7SS), usher family protein 99.7 
KIE68021 Escherichia coli F17 fimbrial usher 99.7 
KUT57088 Escherichia coli F17 fimbrial usher 99.7 
KUX63359 Escherichia coli F17 fimbrial usher 99.7 
KZH92368 Escherichia coli F17 fimbrial usher 99.7 
KZH92802 Escherichia coli F17 fimbrial usher 99.7 
KZJ70388 Escherichia coli F17 fimbrial usher 99.7 
KEJ66138 Escherichia coli 3-020-07_S4_C1 type VII secretion system (T7SS), usher family protein 99.7 
KSW91158 Escherichia coli F17 fimbrial usher 99.7 
KUX58993 Escherichia coli F17 fimbrial usher 99.7 
KKA62248 Escherichia coli 9.1649 fimbrial usher protein 99.8 
KUS56949 Escherichia coli F17 fimbrial usher 99.8 
CAD33726 Escherichia coli putative F17-like fimbrial usher 99.7 
ABG71754 Escherichia coli 536 putative F17-like fimbrial usher 99.6 
EQW45049 Escherichia coli UMEA 3087-1 F17-like fimbrial usher 99.7 
EQW73672 Escherichia coli UMEA 3121-1 F17-like fimbrial usher 99.6 
EQW75725 Escherichia coli UMEA 3121-1 F17-like fimbrial usher 99.6 
EQY34770 Escherichia coli UMEA 3222-1 F17-like fimbrial usher 99.6 
EQY34808 Escherichia coli UMEA 3222-1 F17-like fimbrial usher 99.6 
EQT41795 Escherichia coli HVH 185 (4-2876639) F17-like fimbrial usher 99.8 
EQT46554 Escherichia coli HVH 185 (4-2876639) F17-like fimbrial usher 99.8 
EQU37953 Escherichia coli HVH 204 (4-3112802) F17-like fimbrial usher 99.8 
EQW63376 Escherichia coli UMEA 3113-1 F17-like fimbrial usher 99.8 
EQU40650 Escherichia coli HVH 204 (4-3112802) F17-like fimbrial usher 99.6 
EQQ62500 Escherichia coli HVH 109 (4-6977162) F17-like fimbrial usher 99.6 
EQQ82588 Escherichia coli HVH 114 (4-7037740) F17-like fimbrial usher 99.6 
EQR09972 Escherichia coli HVH 117 (4-6857191) F17-like fimbrial usher 99.6 
EQU89480 Escherichia coli HVH 216 (4-3042952) F17-like fimbrial usher 99.6 
EQY63999 Escherichia coli UMEA 3257-1 F17-like fimbrial usher 99.6 
KLX39893 Escherichia coli F17-like fimbrial usher 99.6 
KLX42170 Escherichia coli F17-like fimbrial usher 99.6 
KTK78416 Escherichia fergusonii F17 fimbrial usher 99.6 
KUV23781 Escherichia coli F17 fimbrial usher 99.6 
KUV45571 Escherichia coli F17 fimbrial usher 99.6 
KXL00261 Escherichia coli F17 fimbrial usher 99.6 
KZI73335 Escherichia coli F17 fimbrial usher 99.6 
EEJ46853 Escherichia coli 83972 fimbrial usher protein 99.7 
ESD40481 Escherichia coli 907892 fimbrial usher protein 99.6 
EFJ55400 Escherichia coli MS 185-1 fimbrial usher protein 99.6 
EFJ93345 Escherichia coli MS 45-1 fimbrial usher protein 99.6 
ADN49244 Escherichia coli ABU 83972 putative F17-like fimbrial usher 99.6 
ELC24324 Escherichia coli KTE15 F17-like fimbrial usher 99.6 
ELC59545 Escherichia coli KTE39 F17-like fimbrial usher 99.6 
ELC84925 Escherichia coli KTE188 F17-like fimbrial usher 99.6 
ELD42488 Escherichia coli KTE214 F17-like fimbrial usher 99.6 
ELD59758 Escherichia coli KTE230 F17-like fimbrial usher 99.6 
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ELE78785 Escherichia coli KTE86 F17-like fimbrial usher 99.6 
ELH41419 Escherichia coli KTE183 F17-like fimbrial usher 99.6 
ELJ74739 Escherichia coli KTE88 F17-like fimbrial usher 99.6 
ELJ98001 Escherichia coli KTE99 F17-like fimbrial usher 99.6 
EOV89522 Escherichia coli KTE89 F17-like fimbrial usher 99.6 
EQO41248 Escherichia coli HVH 39 (4-2679949) F17-like fimbrial usher 99.6 
EQW11354 Escherichia coli UMEA 3022-1 F17-like fimbrial usher 99.6 
EQW13192 Escherichia coli UMEA 3022-1 F17-like fimbrial usher 99.6 
EQW51065 Escherichia coli UMEA 3097-1 F17-like fimbrial usher 99.6 
EQX17451 Escherichia coli UMEA 3161-1 F17-like fimbrial usher 99.6 
EQX36137 Escherichia coli UMEA 3173-1 F17-like fimbrial usher 99.6 
EQY06764 Escherichia coli UMEA 3208-1 F17-like fimbrial usher 99.6 
EQY24271 Escherichia coli UMEA 3217-1 F17-like fimbrial usher 99.6 
EQY50557 Escherichia coli UMEA 3233-1 F17-like fimbrial usher 99.6 
EQY95004 Escherichia coli UMEA 3337-1 F17-like fimbrial usher 99.6 
EQZ06873 Escherichia coli UMEA 3341-1 F17-like fimbrial usher 99.6 
EQZ19130 Escherichia coli UMEA 3490-1 F17-like fimbrial usher 99.6 
ERA47360 Escherichia coli UMEA 4076-1 F17-like fimbrial usher 99.6 
ERA64849 Escherichia coli HVH 156 (4-3206505) F17-like fimbrial usher 99.6 
EQX07927 Escherichia coli UMEA 3159-1 F17-like fimbrial usher 99.6 
EQX39702 Escherichia coli UMEA 3175-1 F17-like fimbrial usher 99.6 
EQX54816 Escherichia coli UMEA 3178-1 F17-like fimbrial usher 99.6 
EQY38465 Escherichia coli UMEA 3221-1 F17-like fimbrial usher 99.6 
EQY41172 Escherichia coli UMEA 3230-1 F17-like fimbrial usher 99.6 
EQZ85064 Escherichia coli UMEA 3707-1 F17-like fimbrial usher 99.6 
EQZ91173 Escherichia coli UMEA 3705-1 F17-like fimbrial usher 99.6 
ETF28844 Escherichia coli HVH 83 (4-2051087) F17-like fimbrial usher 99.6 
EYB58385 Escherichia coli F17 fimbrial usher 99.6 
KEP00361 Escherichia coli F17 fimbrial usher 99.6 
KUW14700 Escherichia coli F17 fimbrial usher 99.6 
KYS70882 Escherichia coli F17 fimbrial usher 99.6 
ELE03318 Escherichia coli KTE53 F17-like fimbrial usher 99.6 
ELE37879 Escherichia coli KTE67 F17-like fimbrial usher 99.6 
ELH68122 Escherichia coli KTE207 F17-like fimbrial usher 99.6 
ELI71746 Escherichia coli KTE133 F17-like fimbrial usher 99.6 
EQN00413 Escherichia coli HVH 2 (4-6943160) F17-like fimbrial usher 99.6 
EQN45609 Escherichia coli HVH 13 (4-7634056) F17-like fimbrial usher 99.6 
EQP06349 Escherichia coli HVH 58 (4-2839709) F17-like fimbrial usher 99.6 
EQQ16954 Escherichia coli HVH 92 (4-5930790) F17-like fimbrial usher 99.6 
EQQ37550 Escherichia coli HVH 96 (4-5934869) F17-like fimbrial usher 99.6 
EQR41036 Escherichia coli HVH 125 (4-2634716) F17-like fimbrial usher 99.6 
EQS92042 Escherichia coli HVH 169 (4-1075578) F17-like fimbrial usher 99.6 
EQU67332 Escherichia coli HVH 212 (3-9305343) F17-like fimbrial usher 99.6 
EQV24276 Escherichia coli HVH 227 (4-2277670) F17-like fimbrial usher 99.6 
EQV64639 Escherichia coli KOEGE 56 (169a) F17-like fimbrial usher 99.6 
ESP19911 Escherichia coli HVH 86 (4-7026218) F17-like fimbrial usher 99.6 
EQR58384 Escherichia coli HVH 132 (4-6876862) F17-like fimbrial usher 99.6 
EQS17497 Escherichia coli HVH 144 (4-4451937) F17-like fimbrial usher 99.6 
EQU92514 Escherichia coli HVH 218 (4-4500903) F17-like fimbrial usher 99.6 
EQV01012 Escherichia coli HVH 220 (4-5876842) F17-like fimbrial usher 99.6 
ERA64868 Escherichia coli HVH 157 (4-3406229) F17-like fimbrial usher 99.6 
ERA79243 Escherichia coli HVH 159 (4-5818141) F17-like fimbrial usher 99.6 
KZI09905 Escherichia coli F17 fimbrial usher 99.6 
EQS44918 Escherichia coli HVH 153 (3-9344314) F17-like fimbrial usher 99.6 
EQY65807 Escherichia coli UMEA 3264-1 F17-like fimbrial usher 99.6 
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EQY74298 Escherichia coli UMEA 3268-1 F17-like fimbrial usher 99.6 
EQZ69900 Escherichia coli UMEA 3687-1 F17-like fimbrial usher 99.6 
EQZ74168 Escherichia coli UMEA 3694-1 F17-like fimbrial usher 99.6 
ERA06117 Escherichia coli UMEA 3821-1 F17-like fimbrial usher 99.6 
ERA44053 Escherichia coli UMEA 4207-1 F17-like fimbrial usher 99.6 
ESJ99313 Escherichia coli HVH 98 (4-5799287) F17-like fimbrial usher 99.6 
ESK27829 Escherichia coli UMEA 3342-1 F17-like fimbrial usher 99.6 
EYB60166 Escherichia coli F17 fimbrial usher 99.6 
KEP02518 Escherichia coli F17 fimbrial usher 99.6 
KHO56518 Escherichia coli F17 fimbrial usher 99.6 
KUS42725 Escherichia coli F17 fimbrial usher 99.6 
EQP44047 Escherichia coli HVH 74 (4-1034782) F17-like fimbrial usher 99.6 
EQT05774 Escherichia coli HVH 172 (4-3248542) F17-like fimbrial usher 99.6 
EQV53030 Escherichia coli KOEGE 43 (105a) F17-like fimbrial usher 99.6 
EQV55245 Escherichia coli KOEGE 44 (106a) F17-like fimbrial usher 99.6 
EQV65664 Escherichia coli KOEGE 61 (174a) F17-like fimbrial usher 99.6 
EQW35180 Escherichia coli UMEA 3053-1 F17-like fimbrial usher 99.6 
EQR30454 Escherichia coli HVH 121 (4-6877826) F17-like fimbrial usher 99.6 
OAC27962 Escherichia coli F17-like fimbrial usher 99.6 
ELJ78821 Escherichia coli KTE94 F17-like fimbrial usher 97.9 
EOX21851 Escherichia coli KTE185 F17-like fimbrial usher 97.9 
ELH20199 Escherichia coli KTE194 F17-like fimbrial usher 79.9 
ELI19171 Escherichia coli KTE113 F17-like fimbrial usher 79.9 
EQV28775 Escherichia coli KOEGE 30 (63a) F17-like fimbrial usher 79.9 
EQW14192 Escherichia coli UMEA 3014-1 F17-like fimbrial usher 79.9 
EQX15781 Escherichia coli UMEA 3160-1 F17-like fimbrial usher 79.9 
EQX72890 Escherichia coli UMEA 3193-1 F17-like fimbrial usher 79.9 
ERA29942 Escherichia coli UMEA 4075-1 F17-like fimbrial usher 79.9 
KXL21895 Escherichia coli F17 fimbrial usher 79.9 
KUW45549 Escherichia coli F17 fimbrial usher 79.9 
AGS60699 Proteus mirabilis BB2000 fimbrial usher protein 79.4 
AND13784 Proteus mirabilis F17 fimbrial usher 79.5 
EKB01574 Proteus mirabilis WGLW6 hypothetical protein 79.5 
KSA05685 Proteus mirabilis F17 fimbrial usher 79.5 
KGA58547 Proteus vulgaris hypothetical protein 79.3 
CAR41290 Proteus mirabilis fimbrial usher protein 79.2 
KGQ15598 Proteus mirabilis F17 fimbrial usher 79.2 
KGA89929 Proteus mirabilis hypothetical protein 79.2 
KGZ05032 Proteus mirabilis F17 fimbrial usher 79.2 
KGZ39655 Proteus mirabilis F17 fimbrial usher 79.1 
KSW14302 Proteus mirabilis F17 fimbrial usher 79.1 
KSW23593 Proteus mirabilis F17 fimbrial usher 79.1 
EEI46422 Proteus mirabilis ATCC 29906 fimbrial usher protein 79.1 
KGY29288 Proteus mirabilis F17 fimbrial usher 79.1 
KGY42554 Proteus mirabilis F17 fimbrial usher 79.1 
KGY46341 Proteus mirabilis F17 fimbrial usher 79.1 
KXB98825 Proteus mirabilis fimbrial usher protein 79 
KKC58837 Proteus mirabilis F17 fimbrial usher 79.1 
ETE47402 Salmonella enterica subsp fimbrial usher protein 58.1 
KUR52793 Salmonella enterica subsp.F17 fimbrial usher 58.1 
CAX67955 Salmonella enterica putative fimbrial biogenesis usher protein 59.1 
EHY70493 Salmonella enterica subsp. fimbrial usher protein 59 
ENZ87754 Salmonella enterica subsp.Outer membrane usher protein htrE precursor 59 
ESE91231 Salmonella enterica subsp.  fimbrial usher protein 60.6 
ANA20601 Salmonella enterica subsp. diarizonae F17 fimbrial usher 59.2 
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ANA24823 Salmonella enterica subsp. diarizonae F17 fimbrial usher 59.2 
ANA29166 Salmonella enterica subsp. diarizonae F17 fimbrial usher 59.2 
ESJ19560 Salmonella enterica subsp fimbrial usher protein 59.3 
ESE86375 Salmonella enterica subsp. fimbrial usher protein 59.5 
ACT33470 Escherichia coli Vir68 F17 fimbrial usher protein 58.9 
EGI36603 Escherichia coli TA271 outer membrane usher protein HifC 58.9 
KHG75394 Escherichia coli F17 fimbrial usher 58.9 
KHI16177 Escherichia coli F17 fimbrial usher 58.9 
KHI55142 Escherichia coli F17 fimbrial usher 58.9 
KXQ50743 Escherichia coli F17 fimbrial usher 58.9 
KIG88168 Escherichia coli F17 fimbrial usher 58.8 
EID64834 Escherichia coli W26 outer membrane usher protein HifC 58.9 
KLG28392 Escherichia coli F17 fimbrial usher 58.9 
KIG29732 Escherichia coli F17 fimbrial usher 58.9 
KHI29822 Escherichia coli F17 fimbrial usher 58.9 
AAA92620 Escherichia coli transmembrane protein 59.6 
ERA04437 Escherichia coli UMEA 3805-1 F17-like fimbrial usher 59.6 
EQO74630 Escherichia coli HVH 46 (4-2758776) F17-like fimbrial usher 59.6 
EQS48079 Escherichia coli HVH 153 (3-9344314) F17-like fimbrial usher 59.6 
KIO84626 Escherichia coli 97.0264 fimbrial usher protein 59.6 
KXL74806 Escherichia coli F17 fimbrial usher 59.6 
KXL87851 Escherichia coli F17 fimbrial usher 59.6 
KXM02269 Escherichia coli F17 fimbrial usher 59.6 
KXM18522 Escherichia coli F17 fimbrial usher 59.6 
KXM45748 Escherichia coli F17 fimbrial usher 59.6 
KXN29657 Escherichia coli F17 fimbrial usher 59.6 
KXN32898 Escherichia coli F17 fimbrial usher 59.6 
OAC11594 Escherichia coli fimbrial transmembrane protein F17a-C 59.6 
OAC27624 Escherichia coli fimbrial transmembrane protein F17a-C 59.7 
KQJ38281 Escherichia coli F17 fimbrial usher 58.8 
EKI47004 Escherichia coli N1 transmembrane protein 58.9 
KHJ08306 Escherichia coli F17 fimbrial usher 59.1 
EGX03870 Escherichia coli STEC_MHI813 outer membrane usher protein hifC 59.6 
EOU64766 Escherichia coli KTE19 F17-like fimbrial usher 59.7 
KHI17420 Escherichia coli F17 fimbrial usher 59 
KIG71063 Escherichia coli F17 fimbrial usher 59 
KHG81555 Escherichia coli F17 fimbrial usher 59.8 
KHH99754 Escherichia coli F17 fimbrial usher 59.8 
KIG38390 Escherichia coli F17 fimbrial usher 59.8 
KHG83618 Escherichia coli F17 fimbrial usher 59.7 
ACT33558 Escherichia coli Vir68 hypothetical protein 42 
EYZ95685 Escherichia coli O119:H4 str. 03-3458 deoxyribonuclease HsdR 42 
EGI36568 Escherichia coli TA271 putative fimbrial usher protein 42 
EKH08978 Escherichia coli FRIK920 putative outer membrane usher protein 43.6 
EKH17933 Escherichia coli PA34 putative outer membrane usher protein 43.6 
EKH20639 Escherichia coli FDA506 putative outer membrane usher protein 43.6 
EKH25450 Escherichia coli FDA507 putative outer membrane usher protein 43.6 
EKH32471 Escherichia coli FDA504 putative outer membrane usher protein 43.6 
EKH39969 Escherichia coli FRIK1999 putative outer membrane usher protein 43.6 
EKH49904 Escherichia coli NE1487 putative outer membrane usher protein 43.6 
EKH59659 Escherichia coli FRIK2001 putative outer membrane usher protein 43.6 
EKH67664 Escherichia coli PA4 putative outer membrane usher protein 43.6 
EKH77367 Escherichia coli PA23 putative outer membrane usher protein 43.6 
EKH77904 Escherichia coli PA49 putative outer membrane usher protein 43.6 
EKH83279 Escherichia coli PA45 putative outer membrane usher protein 43.6 
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EKH92578 Escherichia coli TT12B putative outer membrane usher protein 43.6 
EKH96483 Escherichia coli MA6 putative outer membrane usher protein 43.6 
EKI11323 Escherichia coli CB7326 putative outer membrane usher protein 43.6 
EKI69610 Escherichia coli EC1736 putative outer membrane usher protein 43.6 
EKJ30920 Escherichia coli EC1868 putative outer membrane usher protein 43.6 
EKJ31064 Escherichia coli EC1866 putative outer membrane usher protein 43.6 
EKJ45004 Escherichia coli EC1869 putative outer membrane usher protein 43.6 
EKJ47884 Escherichia coli NE098 putative outer membrane usher protein 43.6 
EKJ49469 Escherichia coli EC1870 putative outer membrane usher protein 43.6 
EKJ63277 Escherichia coli FRIK523 putative outer membrane usher protein 43.6 
EKJ65985 Escherichia coli 0.1304 putative outer membrane usher protein 43.6 
EKK33136 Escherichia coli 5.2239 type VII secretion system (T7SS), usher family protein 43.6 
EKK33786 Escherichia coli 6.0172 putative outer membrane usher protein 43.6 
EKK58486 Escherichia coli 8.0586 type VII secretion system (T7SS), usher family protein 43.6 
EKK78428 Escherichia coli 8.0416 putative outer membrane usher protein 43.6 
EKK89063 Escherichia coli 10.0821 type VII secretion system (T7SS), usher family protein 43.6 
EKV83394 Escherichia coli 89.0511 type VII secretion system (T7SS), usher family protein 43.6 
EKV99677 Escherichia coli 90.2281 type VII secretion system (T7SS), usher family protein 43.6 
EKW00030 Escherichia coli 90.0039 type VII secretion system (T7SS), usher family protein 43.6 
EKW00417 Escherichia coli 90.0091 type VII secretion system (T7SS), usher family protein 43.6 
EKW16280 Escherichia coli 93.0056 type VII secretion system (T7SS), usher family protein 43.6 
EKW16942 Escherichia coli 93.0055 type VII secretion system (T7SS), usher family protein 43.6 
EKW17713 Escherichia coli 94.0618 type VII secretion system (T7SS), usher family protein 43.6 
EKW33758 Escherichia coli 95.0183 type VII secretion system (T7SS), usher family protein 43.6 
EKW48481 Escherichia coli 96.0428 type VII secretion system (T7SS), usher family protein 43.6 
EKW54352 Escherichia coli 96.0939 type VII secretion system (T7SS), usher family protein 43.6 
EKW66086 Escherichia coli 96.0932 type VII secretion system (T7SS), usher family protein 43.6 
EKW81431 Escherichia coli 97.1742 type VII secretion system (T7SS), usher family protein 43.6 
EKW85444 Escherichia coli 97.0007 type VII secretion system (T7SS), usher family protein 43.6 
EKW93747 Escherichia coli 99.0713 type VII secretion system (T7SS), usher family protein 43.6 
EKW95043 Escherichia coli 99.0672 type VII secretion system (T7SS), usher family protein 43.6 
EKY42416 Escherichia coli 96.0109 type VII secretion system (T7SS), usher family protein 43.6 
ELV20957 Escherichia coli 99.0814 type VII secretion system (T7SS), usher family protein 43.6 
ELV28748 Escherichia coli 99.0815 type VII secretion system (T7SS), usher family protein 43.6 
ELV56195 Escherichia coli 99.1753 type VII secretion system (T7SS), usher family protein 43.6 
ELV72838 Escherichia coli ATCC 700728 type VII secretion system (T7SS), usher family protein 43.6 
ELV73067 Escherichia coli PA11 type VII secretion system (T7SS), usher family protein 43.6 
ELV79731 Escherichia coli 99.1805 type VII secretion system (T7SS), usher family protein 43.6 
ELV87097 Escherichia coli PA13 type VII secretion system (T7SS), usher family protein 43.6 
ELV94460 Escherichia coli PA2 type VII secretion system (T7SS), usher family protein 43.6 
ELW08784 Escherichia coli PA8 type VII secretion system (T7SS), usher family protein 43.6 
ELW19147 Escherichia coli 7.1982 type VII secretion system (T7SS), usher family protein 43.6 
ELW21161 Escherichia coli 99.1781 type VII secretion system (T7SS), usher family protein 43.6 
ELW24342 Escherichia coli 99.1762 type VII secretion system (T7SS), usher family protein 43.6 
ELW37584 Escherichia coli 3.4880 type VII secretion system (T7SS), usher family protein 43.6 
ELW42989 Escherichia coli 95.0083 type VII secretion system (T7SS), usher family protein 43.6 
ELW44766 Escherichia coli 99.0670 type VII secretion system (T7SS), usher family protein 43.6 
ERB76857 Escherichia coli B107 type VII secretion system (T7SS), usher family protein 43.6 
ERB87400 Escherichia coli B26-1 type VII secretion system (T7SS), usher family protein 43.6 
ERB97963 Escherichia coli B26-2 type VII secretion system (T7SS), usher family protein 43.6 
ERC04184 Escherichia coli B28-2 type VII secretion system (T7SS), usher family protein 43.6 
ERC05409 Escherichia coli B28-1 type VII secretion system (T7SS), usher family protein 43.6 
ERC12039 Escherichia coli B29-1 type VII secretion system (T7SS), usher family protein 43.6 
ERC21172 Escherichia coli B29-2 type VII secretion system (T7SS), usher family protein 43.6 
ERC23962 Escherichia coli B36-1 type VII secretion system (T7SS), usher family protein 43.6 
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ERC27098 Escherichia coli B36-2 type VII secretion system (T7SS), usher family protein 43.6 
ERC35253 Escherichia coli B7-1 type VII secretion system (T7SS), usher family protein 43.6 
ERC44510 Escherichia coli B7-2 type VII secretion system (T7SS), usher family protein 43.6 
ERC44972 Escherichia coli B93 type VII secretion system (T7SS), usher family protein 43.6 
ERC50784 Escherichia coli B94 type VII secretion system (T7SS), usher family protein 43.6 
ERC69414 Escherichia coli  type VII secretion system (T7SS), usher family protein 43.6 
ERC84429 Escherichia coli T234_00 type VII secretion system (T7SS), usher family protein 43.6 
ERC89721 Escherichia coli 14A type VII secretion system (T7SS), usher family protein 43.6 
ERD03249 Escherichia coli B104 type VII secretion system (T7SS), usher family protein 43.6 
ERD03476 Escherichia coli B103 type VII secretion system (T7SS), usher family protein 43.6 
ERD04377 Escherichia coli 2886-75 type VII secretion system (T7SS), usher family protein 43.6 
ERD18377 Escherichia coli B105 type VII secretion system (T7SS), usher family protein 43.6 
ERD19275 Escherichia coli B106 type VII secretion system (T7SS), usher family protein 43.6 
ERD20316 Escherichia coli B108 type VII secretion system (T7SS), usher family protein 43.6 
ERD33082 Escherichia coli B109 type VII secretion system (T7SS), usher family protein 43.6 
ERD34566 Escherichia coli B112 type VII secretion system (T7SS), usher family protein 43.6 
ERD41195 Escherichia coli B113 type VII secretion system (T7SS), usher family protein 43.6 
ERD50200 Escherichia coli B114 type VII secretion system (T7SS), usher family protein 43.6 
ERD51964 Escherichia coli B15 type VII secretion system (T7SS), usher family protein 43.6 
ERD53995 Escherichia coli B17 type VII secretion system (T7SS), usher family protein 43.6 
ERD66870 Escherichia coli B40-2 type VII secretion system (T7SS), usher family protein 43.6 
ERD67707 Escherichia coli B49-2 type VII secretion system (T7SS), usher family protein 43.6 
ERD68267 Escherichia coli B40-1 type VII secretion system (T7SS), usher family protein 43.6 
ERD80446 Escherichia coli B5-2 type VII secretion system (T7SS), usher family protein 43.6 
ERD83897 Escherichia coli B83 type VII secretion system (T7SS), usher family protein 43.6 
ERD87954 Escherichia coli B84 type VII secretion system (T7SS), usher family protein 43.6 
ERD94118 Escherichia coli B85 type VII secretion system (T7SS), usher family protein 43.6 
ERE09951 Escherichia coli  type VII secretion system (T7SS), usher family protein 43.6 
ERE24559 Escherichia coli T1282_01 type VII secretion system (T7SS), usher family protein 43.6 
ERE35233 Escherichia coli B90 type VII secretion system (T7SS), usher family protein 43.6 
ETJ78460 Escherichia coli ATCC BAA-2192 fimbrial protein 43.6 
EYV59047 Escherichia coli O157:H7 str. 2009EL2109 fimbrial protein 43.6 
EYV68242 Escherichia coli O157:H7 str. 2009EL1705 fimbrial protein 43.6 
EYV81494 Escherichia coli O157:H7 str. K5806 fimbrial protein 43.6 
EYV86677 Escherichia coli O157:H7 str. F7350 fimbrial protein 43.6 
EYW03298 Escherichia coli O157:H7 str. 2011EL-2312 fimbrial protein 43.6 
EYW21095 Escherichia coli O157:H7 str. 2011EL-2114 fimbrial protein 43.6 
EYW38000 Escherichia coli O157:H7 str. 2011EL-2113 fimbrial protein 43.6 
EYW38081 Escherichia coli O157:H7 str. 2011EL-2112 fimbrial protein 43.6 
EYW42507 Escherichia coli O157:H7 str. 2011EL-2111 fimbrial protein 43.6 
EYW47992 Escherichia coli O157:H7 str. 2011EL-2108 fimbrial protein 43.6 
EYW50954 Escherichia coli O157:H7 str. 2011EL-2109 fimbrial protein 43.6 
EYW52560 Escherichia coli O157:H7 str. 2011EL-2107 fimbrial protein 43.6 
EYW58006 Escherichia coli O157:H7 str. 2011EL-2106 fimbrial protein 43.6 
EYW66459 Escherichia coli O157:H7 str. 2011EL-2105 fimbrial protein 43.6 
EYW69628 Escherichia coli O157:H7 str. 2011EL-2104 fimbrial protein 43.6 
EYW78793 Escherichia coli O157:H7 str. 2011EL-2103 fimbrial protein 43.6 
EYW79101 Escherichia coli O157:H7 str. 2011EL-2101 fimbrial protein 43.6 
EYW87064 Escherichia coli O157:H7 str. 2011EL-2099 fimbrial protein 43.6 
EYW92680 Escherichia coli O157:H7 str. 08-4169 fimbrial protein 43.6 
EYX08878 Escherichia coli O157:H7 str. 08-3037 fimbrial protein 43.6 
EYX09370 Escherichia coli O157:H7 str. 08-3527 fimbrial protein 43.6 
EYX22958 Escherichia coli O157:H7 str. 2011EL-2097 fimbrial protein 43.6 
EYX27122 Escherichia coli O157:H7 str. 2011EL-2098 fimbrial protein 43.6 
EYX31783 Escherichia coli O157:H7 str. 2011EL-2096 fimbrial protein 43.6 
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EYX41317 Escherichia coli O157:H7 str. 2011EL-2093 fimbrial protein 43.6 
EYX42359 Escherichia coli O157:H7 str. 2011EL-2094 fimbrial protein 43.6 
EYX49506 Escherichia coli O157:H7 str. 2011EL-2091 fimbrial protein 43.6 
EYX49623 Escherichia coli O157:H7 str. 2011EL-2092 fimbrial protein 43.6 
EYX53190 Escherichia coli O157:H7 str. 2011EL-2090 fimbrial protein 43.6 
EYZ27349 Escherichia coli O157:H7 str. 07-3091 fimbrial protein 43.6 
EYZ39043 Escherichia coli O157:H7 str. 06-4039 fimbrial protein 43.6 
EYZ50667 Escherichia coli O157:H7 str. 06-3745 fimbrial protein 43.6 
EYZ53932 Escherichia coli O55:H7 str. 06-3555 fimbrial protein 43.6 
EZA86831 Escherichia coli O157:H7 str. F6142 fimbrial protein 43.6 
EZA96722 Escherichia coli O157:H7 str. F6750 fimbrial protein 43.6 
EZB05142 Escherichia coli O157:H7 str. F6749 fimbrial protein 43.6 
EZB09946 Escherichia coli O157:H7 str. F6751 fimbrial protein 43.6 
EZB13848 Escherichia coli O157:H7 str. F7377 fimbrial protein 43.6 
EZB34113 Escherichia coli O157:H7 str. H2495 fimbrial protein 43.6 
EZB34923 Escherichia coli O157:H7 str. G5303 fimbrial protein 43.6 
EZB41263 Escherichia coli O157:H7 str. K1420 fimbrial protein 43.6 
EZB51029 Escherichia coli O157:H7 str. K1793 fimbrial protein 43.6 
EZB57624 Escherichia coli O157:H7 str. K1792 fimbrial protein 43.6 
EZB68752 Escherichia coli O157:H7 str. K1795 fimbrial protein 43.6 
EZB70893 Escherichia coli O157:H7 str. K1796 fimbrial protein 43.6 
EZB76896 Escherichia coli O157:H7 str. K1845 fimbrial protein 43.6 
EZB84586 Escherichia coli O157:H7 str. K1927 fimbrial protein 43.6 
EZB85896 Escherichia coli O157:H7 str. K2188 fimbrial protein 43.6 
EZB86437 Escherichia coli O157:H7 str. K1921 fimbrial protein 43.6 
EZB93552 Escherichia coli O157:H7 str. K2192 fimbrial protein 43.6 
EZB97777 Escherichia coli O157:H7 str. K2324 fimbrial protein 43.6 
EZC02291 Escherichia coli O157:H7 str. K2191 fimbrial protein 43.6 
EZC11600 Escherichia coli O157:H7 str. K2581 fimbrial protein 43.6 
EZC16351 Escherichia coli O157:H7 str. K2622 fimbrial protein 43.6 
EZC20510 Escherichia coli O157:H7 str. K2845 fimbrial protein 43.6 
EZC23600 Escherichia coli O157:H7 str. K2854 fimbrial protein 43.6 
EZC33166 Escherichia coli O157:H7 str. K4396 fimbrial protein 43.6 
EZC64017 Escherichia coli O157:H7 str. K5453 fimbrial protein 43.6 
EZC65918 Escherichia coli O157:H7 str. K5448 fimbrial protein 43.6 
EZC69249 Escherichia coli O157:H7 str. K5449 fimbrial protein 43.6 
EZC78925 Escherichia coli O157:H7 str. K5460 fimbrial protein 43.6 
EZC79564 Escherichia coli O157:H7 str. K5602 fimbrial protein 43.6 
EZC86329 Escherichia coli O157:H7 str. K5467 fimbrial protein 43.6 
EZC93672 Escherichia coli O157:H7 str. K5607 fimbrial protein 43.6 
EZC99468 Escherichia coli O157:H7 str. K5609 fimbrial protein 43.6 
EZD03089 Escherichia coli O157:H7 str. K5852 fimbrial protein 43.6 
EZD13398 Escherichia coli O157:H7 str. K6590 fimbrial protein 43.6 
EZD75223 Escherichia coli O157:H7 str. K7140 fimbrial protein 43.6 
EZD89123 Escherichia coli O157:NM str. 08-4540 fimbrial protein 43.6 
EZE56112 Escherichia coli O157:H7 str. 2009C-4258 fimbrial protein 43.6 
EZE82006 Escherichia coli O157:H7 str. 2009EL1449 fimbrial protein 43.6 
EZF03468 Escherichia coli O157:H7 str. 2011EL-2313 fimbrial protein 43.6 
EZQ44480 Escherichia coli O157: str. 2010EL-2045 fimbrial protein 43.6 
EZQ53020 Escherichia coli O157: str. 2010EL-2044 fimbrial protein 43.6 
KIY27912 Escherichia coli fimbrial protein 43.6 
KIZ10804 Escherichia coli fimbrial protein 43.6 
KKF84503 Escherichia coli O157:H7 fimbrial protein 43.6 
KKK27660 Escherichia coli fimbrial protein 43.6 
KKY48541 Escherichia coli O157:H7 fimbrial protein 43.6 
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KOZ06857 Escherichia coli fimbrial protein 43.6 
KOZ10810 Escherichia coli fimbrial protein 43.6 
KOZ16101 Escherichia coli fimbrial protein 43.6 
KOZ29806 Escherichia coli fimbrial protein 43.6 
KOZ48678 Escherichia coli fimbrial protein 43.6 
KOZ53952 Escherichia coli fimbrial protein 43.6 
KOZ57012 Escherichia coli fimbrial protein 43.6 
KOZ72847 Escherichia coli fimbrial protein 43.6 
KOZ97762 Escherichia coli fimbrial protein 43.6 
KPH29271 Escherichia coli fimbrial protein 43.6 
KPH37240 Escherichia coli fimbrial protein 43.6 
KPH42145 Escherichia coli fimbrial protein 43.6 
KPP14588 Escherichia coli fimbrial protein 43.6 
KPP19808 Escherichia coli fimbrial protein 43.6 
KPP35187 Escherichia coli fimbrial protein 43.6 
KPP45378 Escherichia coli fimbrial protein 43.6 
KPP48065 Escherichia coli fimbrial protein 43.6 
KPP51659 Escherichia coli fimbrial protein 43.6 
KRQ15005 Escherichia coli O157:H7 fimbrial protein 43.6 
KYT92957 Escherichia coli fimbrial protein 43.6 
ADD55863 Escherichia coli O55:H7 str. CB9615 Putative outer membrane usher protein 43.6 
AEZ39843 Escherichia coli O55:H7 str. RM12579 outer membrane usher protein 43.6 
AFJ28284 Escherichia coli Xuzhou21 putative outer membrane usher protein 43.6 
AIG67653 Escherichia coli O157:H7 str. EDL933 outer membrane fimbrial usher protein 43.6 
ALH91049 Escherichia coli O157:H7 fimbrial protein 43.6 
AMW50839 Escherichia coli fimbrial protein 43.6 
ANE66650 Escherichia coli fimbrial protein 43.6 
ANG67852 Escherichia coli O157:H7 fimbrial protein 43.6 
ANG73402 Escherichia coli O157:H7 fimbrial protein 43.6 
ANG79029 Escherichia coli O157:H7 fimbrial protein 43.6 
ANW39262 Escherichia coli O157:H7 fimbrial protein 43.6 
AOD12137 Escherichia coli fimbrial protein 43.6 
BAB34701 Escherichia coli O157:H7 str. Sakai putative outer membrane usher protein 43.6 
EDU87258 Escherichia coli O157:H7 str. EC4501 fimbrial usher protein 43.6 
EDU89867 Escherichia coli O157:H7 str. EC869 fimbrial usher protein 43.6 
EDU96778 Escherichia coli O157:H7 str. EC508 fimbrial usher protein 43.6 
EEC27388 Escherichia coli O157:H7 str. TW14588 fimbrial usher protein 43.6 
EFW67105 Escherichia coli O157:H7 str. EC1212 putative outer membrane usher protein 43.6 
EFX21873 Escherichia coli O55:H7 str. 3256-97 putative outer membrane usher protein 43.6 
EGD62345 Escherichia coli O157:H7 str. 1125 putative outer membrane usher protein 43.6 
EGD69322 Escherichia coli O157:H7 str. 1044 putative outer membrane usher protein 43.6 
EHU62991 Escherichia coli DEC3A fimbrial Usher family protein 43.6 
EHU75376 Escherichia coli DEC3C fimbrial Usher family protein 43.6 
EHU80135 Escherichia coli DEC3D fimbrial Usher family protein 43.6 
EHU81960 Escherichia coli DEC3E fimbrial Usher family protein 43.6 
EHU95993 Escherichia coli DEC4A fimbrial Usher family protein 43.6 
EHV00739 Escherichia coli DEC4B fimbrial Usher family protein 43.6 
EHV11958 Escherichia coli DEC4C fimbrial Usher family protein 43.6 
EHV12403 Escherichia coli DEC4D fimbrial Usher family protein 43.6 
EHV27572 Escherichia coli DEC4F fimbrial Usher family protein 43.6 
EHV28099 Escherichia coli DEC5A fimbrial Usher family protein 43.6 
EHV34607 Escherichia coli DEC5B fimbrial Usher family protein 43.6 
EHV41319 Escherichia coli DEC5C fimbrial Usher family protein 43.6 
EIN27548 Escherichia coli FRIK1996 putative outer membrane usher protein 43.6 
EIN28653 Escherichia coli FDA517 putative outer membrane usher protein 43.6 
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EIN44971 Escherichia coli 93-001 putative outer membrane usher protein 43.6 
EIN47324 Escherichia coli FRIK1985 putative outer membrane usher protein 43.6 
EIN80149 Escherichia coli PA10 putative outer membrane usher protein 43.6 
EIN81204 Escherichia coli PA15 putative outer membrane usher protein 43.6 
EIN91451 Escherichia coli PA22 putative outer membrane usher protein 43.6 
EIO20073 Escherichia coli PA31 putative outer membrane usher protein 43.6 
EIO20293 Escherichia coli PA32 putative outer membrane usher protein 43.6 
EIO22332 Escherichia coli PA33 putative outer membrane usher protein 43.6 
EIO30655 Escherichia coli PA40 putative outer membrane usher protein 43.6 
EIO43631 Escherichia coli PA42 putative outer membrane usher protein 43.6 
EIO44995 Escherichia coli PA39 putative outer membrane usher protein 43.6 
EIO61076 Escherichia coli TW10246 putative outer membrane usher protein 43.6 
EIO67789 Escherichia coli TW11039 putative outer membrane usher protein 43.6 
EIO71388 Escherichia coli TW07945 putative outer membrane usher protein 43.6 
EIO84707 Escherichia coli TW10119 putative outer membrane usher protein 43.6 
EIO85331 Escherichia coli TW09098 putative outer membrane usher protein 43.6 
EIP16971 Escherichia coli TW14301 putative outer membrane usher protein 43.6 
EIP18683 Escherichia coli O157:H7 str. TW14313 putative outer membrane usher protein 43.6 
EIP19202 Escherichia coli EC4421 putative outer membrane usher protein 43.6 
EIP30962 Escherichia coli EC4422 putative outer membrane usher protein 43.6 
EIP49382 Escherichia coli EC4436 putative outer membrane usher protein 43.6 
EIP61961 Escherichia coli EC1738 putative outer membrane usher protein 43.6 
EIP64455 Escherichia coli EC4437 putative outer membrane usher protein 43.6 
EIP69570 Escherichia coli EC1734 putative outer membrane usher protein 43.6 
EIP81532 Escherichia coli EC1863 putative outer membrane usher protein 43.6 
EKK33536 Escherichia coli 3.4870 type VII secretion system (T7SS), usher family protein 43.6 
OAN04922 Escherichia coli O157:H7 fimbrial protein 43.6 
AAG55651 Escherichia coli O157:H7 str. EDL933 putative usher protein 43.6 
CTR59674 Escherichia coli usher protein 43.6 
CTS24352 Escherichia coli usher protein 43.6 
CTV79962 Escherichia coli usher protein 43.6 
CUA30582 Escherichia coli usher protein 43.6 
EFX27205 Escherichia coli O55:H7 str. USDA 5905 putative outer membrane usher protein 43.6 
EKH97331 Escherichia coli 5905 putative outer membrane usher protein 43.6 
EFX31563 Escherichia coli O157:H7 str. LSU-61 putative outer membrane usher protein 43.6 
EKW70091 Escherichia coli 96.0107 type VII secretion system (T7SS), usher family protein 43.6 
ERC71947 Escherichia coli Bd5610_99 type VII secretion system (T7SS), usher family protein 43.5 
ERC88804 Escherichia coli T924_01 type VII secretion system (T7SS), usher family protein 43.6 
KOZ32122 Escherichia coli fimbrial protein 43.6 
EZB38362 Escherichia coli O157:H7 str. H2498 fimbrial protein 43.5 
KOZ19538 Escherichia coli fimbrial protein 43.6 
KPO75320 Escherichia coli fimbrial protein 43.5 
KPP21245 Escherichia coli fimbrial protein 43.5 
EFX12225 Escherichia coli O157:H- str. 493-89 putative outer membrane usher protein 43.5 
EFX17137 Escherichia coli O157:H- str. H 2687 putative outer membrane usher protein 43.5 
EHU93417 Escherichia coli DEC3F fimbrial Usher family protein 43.5 
EIO52001 Escherichia coli TW06591 putative outer membrane usher protein 43.5 
EKI14407 Escherichia coli 5412 putative outer membrane usher protein 43.5 
KJJ47841 Escherichia coli fimbrial protein 43.5 
KOZ57645 Escherichia coli fimbrial protein 43.5 
KOZ67216 Escherichia coli fimbrial protein 43.5 
KOZ82091 Escherichia coli fimbrial protein 43.5 
KOZ82732 Escherichia coli fimbrial protein 43.5 
KOZ92844 Escherichia coli fimbrial protein 43.5 
EFX07263 Escherichia coli O157:H7 str. G5101 putative outer membrane usher protein 43.7 
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EKI14888 Escherichia coli EC96038 putative outer membrane usher protein 43.7 
EKK75680 Escherichia coli 10.0869 type VII secretion system (T7SS), usher family protein 43.7 
ELW04498 Escherichia coli PA48 type VII secretion system (T7SS), usher family protein 43.7 
EYY42224 Escherichia coli O157:H7 str. 2010C-4979C1 fimbrial protein 43.7 
EHU64177 Escherichia coli DEC3B fimbrial Usher family protein 43.6 
EHV42696 Escherichia coli DEC5D fimbrial Usher family protein 43.6 
EIN28899 Escherichia coli FDA505 putative outer membrane usher protein 43.6 
EIN47052 Escherichia coli FRIK1990 putative outer membrane usher protein 43.6 
EIN64062 Escherichia coli PA5 putative outer membrane usher protein 43.6 
EIN64660 Escherichia coli PA9 putative outer membrane usher protein 43.6 
EIN81979 Escherichia coli PA14 putative outer membrane usher protein 43.6 
EIO05906 Escherichia coli PA28 putative outer membrane usher protein 43.6 
EIO42576 Escherichia coli PA41 putative outer membrane usher protein 43.6 
EIP02169 Escherichia coli TW09195 putative outer membrane usher protein 43.6 
EKH46243 Escherichia coli FRIK1997 putative outer membrane usher protein 43.6 
EKI52599 Escherichia coli PA38 putative outer membrane usher protein 43.6 
EKI72347 Escherichia coli EC1737 putative outer membrane usher protein 43.6 
EKJ16694 Escherichia coli EC1864 putative outer membrane usher protein 43.6 
EKK61703 Escherichia coli 8.2524 type VII secretion system (T7SS), usher family protein 43.6 
EKV82226 Escherichia coli 88.1042 type VII secretion system (T7SS), usher family protein 43.6 
EKV83788 Escherichia coli 88.1467 type VII secretion system (T7SS), usher family protein 43.6 
EKW33566 Escherichia coli 95.0943 type VII secretion system (T7SS), usher family protein 43.6 
EKW52543 Escherichia coli 96.0427 type VII secretion system (T7SS), usher family protein 43.6 
EKW66188 Escherichia coli 97.0003 type VII secretion system (T7SS), usher family protein 43.6 
EKY43968 Escherichia coli 97.0010 type VII secretion system (T7SS), usher family protein 43.6 
ELV42265 Escherichia coli 99.0816 type VII secretion system (T7SS), usher family protein 43.6 
ELV59010 Escherichia coli 99.1775 type VII secretion system (T7SS), usher family protein 43.6 
ELV60235 Escherichia coli 99.1793 type VII secretion system (T7SS), usher family protein 43.6 
ERB87602 Escherichia coli B102 type VII secretion system (T7SS), usher family protein 43.6 
ERD95759 Escherichia coli B86 type VII secretion system (T7SS), usher family protein 43.6 
ERE34518 Escherichia coli B89 type VII secretion system (T7SS), usher family protein 43.6 
ERE38404 Escherichia coli Tx1686 type VII secretion system (T7SS), usher family protein 43.6 
ERE19084 Escherichia coli 09BKT024447 type VII secretion system (T7SS), usher family protein 43.6 
EKI58398 Escherichia coli EC1735 putative outer membrane usher protein 43.6 
EKH58316 Escherichia coli NE037 putative outer membrane usher protein 43.8 
EHV49910 Escherichia coli DEC5E fimbrial Usher family protein 41.9 
CTT89937 Escherichia coli usher protein 43.6 
EFF07341 Escherichia coli B185 outer membrane usher protein 43.6 
KOA35398 Escherichia coli fimbrial protein 43.6 
EGX10205 Escherichia coli STEC_MHI813 fimbrial Usher family protein 43.5 
KJW46289 Escherichia coli fimbrial protein 43.5 
ELG90062 Escherichia coli KTE146 hypothetical protein 43.4 
ANO88318 Escherichia coli fimbrial protein 43.3 
EHN88119 Escherichia coli TA124 hypothetical protein 43.4 
CDP68350 Escherichia coli D6-113.11 Putative outer membrane usher protein 43.7 
CDU35541 Escherichia coli D6-113.11 Putative outer membrane usher protein 43.7 
KHI45262 Escherichia coli fimbrial protein 43.8 
KUS76798 Escherichia coli fimbrial protein 43.8 
ELC99050 Escherichia coli KTE193 hypothetical protein 43.6 
ELI31921 Escherichia coli KTE112 hypothetical protein 43.6 
EQZ68447 Escherichia coli UMEA 3671-1 hypothetical protein 43.7 
EQW90693 Escherichia coli UMEA 3124-1 hypothetical protein 43.9 
EGI22399 Escherichia coli M718 putative fimbrial usher protein 43.5 
KNZ99685 Escherichia coli fimbrial protein 43.5 
ESA67030 Escherichia coli 113290 fimbrial usher protein 43.7 
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KFD74598 Escherichia coli fimbrial protein 43.7 
ESM39020 Escherichia coli BWH 32 hypothetical protein 43.6 
KYT01105 Escherichia coli fimbrial protein 43.8 
KYU52385 Escherichia coli fimbrial protein 43.8 
EHN96543 Escherichia coli E101 hypothetical protein 43.8 
EQZ93543 Escherichia coli UMEA 3718-1 hypothetical protein 43.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: The carriage of F17-like pili in rUTI UPEC strains. 
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Strain Pathotype Clade BioProject 
F17-like 
Carriage 
Sample Time 
Point** 
536 UPEC B2 PRJNA16235 Yes 
 11128 EHEC B1 PRJDA32513 
  11368 EHEC B1 PRJDA32509   
 12009 EHEC B1 PRJDA32511 
  55989 EAEC B1 PRJNA33413   
 2009EL-2050 EHEC B1 PRJNA81097 
  2009EL-2071 EHEC B1 PRJNA81099   
 2011C-3493 EHEC B1 PRJNA81095 
  ABU 83972 ABU B2 PRJNA38725 Yes 
 APEC O1 APEC B2 PRJNA16718 
  APEC O78 APEC B1 PRJNA184588   
 ATCC 8739 Commensal A PRJNA18083 
  BL21(DE3) Lab Strain A PRJNA20713   
 BW2952 Lab Strain A PRJNA33775 
  CB9615 EPEC E PRJNA42729   
 CE10 NMEC F PRJNA63597 
  CFT073 UPEC B2 PRJNA313   
 clone D i14 UPEC B2 PRJNA52023 
  clone D i2 UPEC B2 PRJNA52021   
 DH1 Lab Strain A PRJDA52077 
  DH10B Lab Strain A PRJNA20079   
 E2348/69 EPEC B2 PRJEA32571 
  E24377A ETEC B1 PRJNA13960   
 EC4115 EHEC E PRJNA27739 
  ED1a Commensal B2 PRJNA33409   
 EDL933 EHEC E PRJNA259 
  H10407 ETEC A PRJEA42749   
 HS Commensal A PRJNA13959 
  IAI39 UPEC F PRJNA33411   
 IHE3034 NMEC B2 PRJNA43693 
  K12 MG1655 Commensal A PRJNA40075   
 LF82 AIEC B2 PRJNA33825 
  NRG 857C AIEC B2 PRJNA41221   
 REL606 Lab Strain A PRJNA18281 
  RM12579 EPEC E PRJNA68245   
 S88 Commensal B2 PRJNA33375 
  SE11 Commensal B1 PRJNA18057   
 SE15 Commensal B2 PRJDA19053 
  SMS-3-5 Environmental F PRJNA19469   
 TW14359 EHEC E PRJNA30045 
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UM146 AIEC B2 PRJNA50883 Yes 
 UMNK88 ETEC A PRJNA42137 
  UTI89 UPEC B2 PRJNA16259 Yes 
 W Lab Strain B1 PRJNA48011 
  W3110 Lab Strain A PRJNA16351   
 Xuzhou21 EHEC E PRJNA45823 
  2.1a* UPEC A PRJNA269984  Enrollment UTI  
2.2r* UPEC D PRJNA269984  
Different-strain 
rUTI  
5.1a* UPEC B1 PRJNA269984  Enrollment UTI  
5.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
5.3r* UPEC B2 PRJNA269984 Yes 
Different-strain 
rUTI  
9.1a* UPEC D PRJNA269984  Enrollment UTI  
9.2p* UPEC B1 PRJNA269984  Prior to Recurrence  
9.3r* UPEC B1 PRJNA269984  
Different-strain 
rUTI  
11.1a* UPEC A PRJNA269984  Enrollment UTI  
11.2p* UPEC A PRJNA269984  Prior to Recurrence  
11.3r* UPEC A PRJNA269984  Same-strain rUTI  
12.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
12.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
12.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
12.4r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
17.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
17.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
17.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
20.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
20.2r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
20.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
21.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
21.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
21.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
26.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
26.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
26.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
31.1a* UPEC B1 PRJNA269984  Enrollment UTI  
31.2p* UPEC B1 PRJNA269984  Prior to Recurrence  
31.3r* UPEC B2 PRJNA269984  
Different-strain 
rUTI  
34.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
34.2r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
35.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
35.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
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35.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
41.1a* UPEC B2 PRJNA269984 Yes Enrollment UTI  
41.2p* UPEC B2 PRJNA269984 Yes Prior to Recurrence  
41.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
41.4p* UPEC B1 PRJNA269984  Prior to Recurrence  
41.5r* UPEC B1 PRJNA269984  
Different-strain 
rUTI  
56.1a* UPEC B1 PRJNA269984  Enrollment UTI 
56.2r* UPEC B2 PRJNA269984 Yes 
Different-strain 
rUTI  
56.3r* UPEC B2 PRJNA269984 Yes Same-strain rUTI  
	 	 	 	 	 	*	Collected	during	a	previous	longitudinal	study	on	recurrent	UTI	(ref.	18)	
**	Sample	time	point	as	defined	in	[REF]	
	 	 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3: UclD X-ray collection and refinement statistics 
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 HRUclDLD 
(5NWP) 
UclDLD 
(5VQ5) 
Data collection   
Space group P21 P212121 
Cell dimensions     
    a, b, c (Å) 31.0, 91.9, 64.9 39.0, 58.6, 175.1 
    α, β, γ (°)  90.0, 96.5, 90.0 90.0, 90.0, 90.0 
Resolution (Å) a 91.87 – 1.05 (1.11-
1.05) 
55.60-1.6 (1.66-
1.60) 
Rmerge a 0.079 (0.336) 0.05 (0.43) 
I/σ(I) a 11.9 (2.1) 17.68 (1.43) 
CC1/2 a 99.6 (86.0) 0.998 (0.659) 
Completeness (%)a 88.6 (43.8) 99.97 (99.98) 
Redundancy a 5.0 (2.0) 2.0 (2.0) 
   
Refinement   
Resolution (Å) 91.87 - 1.05 55.60 - 1.60 
No. reflections 144393 108142 
Rwork / Rfree 0.118 / 0.143 0.172 / 0.218 
No. atoms 6890 3289 
    Protein 6223 2804 
    Iodide / 6 
    Sulphate 1 / 
    Water 662 479 
B factors   
    Protein 10.7 22.4 
    Iodide / 62.6 
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    Sulphate 11.0 / 
    Water 23.9 36.2 
R.m.s. deviations   
    Bond lengths (Å) 0.028 0.002 
    Bond angles (°) 2.281 0.58 
Number of crystals for each structure should be noted in footnote.  
a Values in parentheses are for highest-resolution shell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
